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RNA-Seq Reveals Transcriptomic Program Associated with Stemness in Taxane 
Resistant Prostate Cancer 
 
by 
Christina K. Cajigas-Du Ross 
Doctor of Philosophy, Graduate Program in Microbiology and Molecular Genetics 
Loma Linda University, August 2018 
Dr. Carlos A. Casiano, Chairperson 
 
There is no cure for advanced prostate cancer (PCa), and taxane chemotherapy is 
the only treatment option once other therapies have failed. However, this is problematic 
since all patients eventually develop chemoresistance. Emerging treatments for advanced 
PCa have shown promise at the benchside, but clinical trials have not resulted in newly 
approved drugs due in part to redundant survival pathways utilized by prostate tumor 
cells to maintain therapy-resistance. Using RNAsequencing—an innovative approach for 
quantifying gene expression changes—this dissertation sought to elucidate 
chemoresistance-associated molecular pathways as a catalyst to develop new therapeutic 
targets. Results revealed a differential upregulation of stemness-associated genes in PCa 
cells selected for chemoresistance. In addition, chemoresistant cells formed robust stem 
cell prostaspheres compared to chemosensitive cells, and expressed other markers of 
cancer stem cells. Overall, these findings support the hypothesis that PCa 
chemoresistance is driven by cancer stem cells.  
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CHAPTER ONE 
INTRODUCTION 
Prostate Cancer Background and Available Therapies 
 Prostate cancer (PCa) is currently the most commonly diagnosed cancer and the 
second leading cause of cancer deaths in American men with 164,690 estimated new 
cases and 29,430 deaths projected in 2018 [1]. PCa also exhibits a striking racial 
disparity, as African American men are 1.4 times greater risk of being diagnosed and 2.5 
times more likely to die of this disease compared to Non-Hispanic white males [2, 3]. In 
addition, African American men are diagnosed with PCa at an earlier age and with a 
more advanced stage compared with Non-Hispanic white men, which may partially 
explain the significant mortality disparity seen in this population. Although PCa 
disproportionately and aggressively affects African American men [2, 3], this group is 
still underrepresented in potentially life-saving clinical trials. Furthermore, this 
underrepresentation could affect the development of newer cancer treatments since 
specific molecular targets might be more sensitive to slight differences in genetic 
variation seen across different ethnic or racial backgrounds [4]. The likelihood of being 
diagnosed with PCa increases with age; this is problematic considering the increasing 
aging male population. Therefore, the aging male population and the complexity of 
addressing the mortality disparity make developing new effective treatments for PCa 
crucial for tackling this public health dilemma and the subsequent fiscal burden that is 
expected over the next few decades [2-5]. 
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PCa Screening and Diagnosis  
 PCa is diagnosed in patients through a combination of screening procedures. 
Digital rectal examination (DRE) is typically performed by a primary care physician. The 
DRE allows the physician to detect abnormal size or hard nodules of the prostate. The 
prostate-specific antigen (PSA) blood test is a screening tool used in combination with 
DRE. PSA is synthesized in the prostate and the concentration in the blood increases with 
PCa [6]. Circulating serum PSA is considered high or abnormal when detected above 4 
ng/ml [7]. While elevated levels of PSA are not always indicative of PCa, it often 
requires follow-up monitoring or screening, including biopsy.  
 Once a tissue sample of the prostate is removed for biopsy, a pathologist is able to 
assign a Gleason score, which is used by the physician to determine aggressiveness and 
stage of the cancer. The higher the Gleason score, the more likely the PCa will spread 
rapidly and be aggressive [8]. Gleason scores range from a value of 1-5 with number 1 
representing small uniform glands and number 3 representing moderately differentiated 
cells with infiltration of cells from glands at the margins. A score higher than 3 represents 
poorly differentiated and anaplastic cells with irregular masses of neoplastic cells and 
lack of glands [8]. PCa biopsies typically reveal phenotypic heterogeneity of histological 
subtypes found in the prostate adenocarcinoma cells. They include luminal secretory, 
neuroendocrine, basal, and luminal epithelial cells [9]. As a result of this heterogeneity, 
the pathologist may identify the two most common grades and add them to determine the 
combined Gleason score, which can range from 6-10. A PCa diagnosis typically occurs 
when the combined Gleason score is at least 6, with scores above 7 indicative of 
aggressive PCa.  
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The heterogeneity of this malignancy makes it an enormous challenge to develop 
therapeutic strategies that will be effective for all PCa patients. At early stages, treatment 
options including radical prostatectomy and radiation can be curative. But treatment 
options for advanced-stage diagnosis including androgen deprivation therapy (ADT) and 
taxane chemotherapy are not as effective since the disease has progressed and is 
phenotypically aggressive (Figure 1). Therefore, a diagnosis with advanced PCa is 
problematic for the patient given the lack of curative options.  
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Figure 1. Prostate Progression and Treatment Options. Stages and treatment options 
available for PCa. PCa is curable if treated while localized in the prostate. Unfortunately, 
once tumor cells migrate out of the organ, the disease is no longer curable and treatments 
are only meant to delay disease progression. ADT is the main treatment option at any 
state of PCa, especially following biochemical recurrence. Metastatic castration resistant 
PCa is treated with taxane chemotherapy and secondary ADT. Once a patient is terminal 
and no longer responding to chemotherapy, palliative care is the only treatment option 
available. 
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Androgen Receptor and ADT 
 Men initially diagnosed with PCa are given several treatment options including 
prostatectomy (prostate removal) or radiation to destroy cancerous cells still remaining in 
the prostate capsule after removal. Many patients, however, are not cured by these 
treatments and their cancer returns [10]. This is typically detected by an increased in PSA 
levels, known as biochemical recurrence. For men diagnosed with advanced PCa, 
treatment with curative intent is no longer an option, and ADT remains the main 
therapeutic modality [10, 11]; this is because prostate tumor growth is initially dependent 
on androgens. Testosterone, secreted primarily by the testes, is the main circulating 
androgen that is secreted in the blood. When testosterone enters the prostate cells, 90% is 
converted to a more active hormone dihydrotestosterone (DHT) by the enzyme 5-alpha-
reductase. DHT has a 5-fold higher affinity for androgen receptor (AR) than testosterone 
[10, 11]. AR is a nuclear receptor comprised of an amino-terminal activating domain, a 
carboxy-terminal ligand-binding domain, and a DNA-binding domain. In its basal state, 
AR is bound to heat-shock proteins in a conformation that prevents DNA binding. 
Androgen binding to AR induces a conformational change that causes dissocation from 
binding proteins and leads to the formation of AR homodimer complexes that can bind to 
androgen response elements in the promoter regions of target genes that contribute to 
cancer progression and aggressiveness [10].  
 ADT includes any treatment that suppresses androgen activity by decreasing 
androgen production through medical castration or by using anti-androgens to block AR 
signaling. The benefit of ADT in PCa treatment is the upregulation of pro-apoptotic 
genes that are normally repressed by AR activation [12], leading to a temporary reduction 
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in tumor aggressiveness. Common anti-androgens include cyproterone acetate, flutamide, 
nilutamide, and bicalutamide, all of which block androgens from binding to AR receptor 
(antagonists). Medical ADT is most commonly used in combination with long-acting 
gonadotrophin-releasing hormone (GnRH) agonists that are equally effective in reducing 
testosterone levels as removal of the testes with less detrimental effects. In addition, 
prostate tumors express GnRH receptors and GnRH analogs are shown preclinically to 
have antitumor activity [12].  
 
Castration-Resistant PCa  
 Despite the imporant clinical benefits seen with ADT including improved 
survival, less morbidity, and better quality of life, it is not curative. This is because, after 
an average of  2-3 years of ADT, PCa cells reactivate AR signaling and continue to 
proliferate despite extremely low levels of circulating testosterone, a stage called 
castration-resistant prostate cancer (CRPC) [11, 12]. Cells bypass AR targeting through a 
variety of mechanisms including AR amplification and mutation, co-activator and co-
repressor modifications, aberrant activation/post-translational modification, altered 
steroidogenesis, the presence of AR splice variants, and as discussed below, 
glucocorticoid receptor bypass [11].  
 AR amplification and increased AR sensitivity are both utilized by PCa cells to 
bypass androgen ablation therapy, and both mechanisms are dependent on androgens 
being present. By amplifying expression of the AR gene, cells have an increased number 
of AR resulting in increased AR expression and enhanced ligand-occupied receptor 
content despite low androgen concentrations [11, 12]. This is most likely achieved 
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through clonal selection of cells that proliferate despite low levels of circulating 
androgens as evidenced by the fact that tumors were found to have this AR amplification 
only after androgen ablation [10]. Increased AR sensitvity is another mechanism that 
results in AR signaling activation despite low androgens. This pathway results in high 
AR expression, increased stability and enhanced nuclear localization of AR in tumor cells 
[10]. Finally, PCa cells can also increase local production of androgens by elevating 5-
alpha-reductatse activity thereby increasing the rate of conversion of testosterone to DHT 
[10].  
 PCa cells can also undergo AR point mutations causing an increase in AR activity 
in response to low circulating androgens. These mutations can also broaden the ligand 
pool to which AR responds, causing PCa cells to circumvent normal growth regulation by 
androgens. These mutations lead to aberrant activation of the androgen signaling axis by 
decreasing the specifity of ligand binding, and allow the ability for non-androgenic 
steroids and androgen antagonists to bind to AR and activate transcription of AR target 
genes [10]. Another pathway by which AR can be activated includes mutations to the 
many co-activators and co-repressors that function normally to regulate AR activation. 
Mutations to the co-regulator complexes can improve androgen-stimulated AR activation 
and also lead to disease progression [10, 11].  
Metastatic CRPC (mCRPC) is a lethal stage of PCa that is marked by recurrence 
of elevated PSA and progression of metastatic lesions [10]. Since 2004, the standard first-
line chemotherapeutic agent for mCRPC has been the taxane drug docetaxel (DTX), a 
microtubule-stabilizing agent that moderately increases overall survival [13, 14]. 
Eventually, however, chemoresistance occurs in all DTX-treated patients resulting in 
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continued disease progression ultimately leading to patient death [15]. Research focusing 
on the mechanisms of DTX-resistance have led to the development of new treatment 
options for mCRPC to target those pathways implicated. They include the next-
generation AR-targeting agents abiraterone acetate and enzalutamide, therapeutic 
vaccines, and the second generation taxane cabazitaxel [15, 16]. Abiraterone acetate is an 
inhibitor of cytochrome P-450 17A1, the enzyme crucial for androgen biosynthesis. 
Unlike GnRH analogs, abiraterone acetate reduces androgen synthesis at the adrenal, 
prostate, and intratumoral sites. Enzalutamide is a more potent AR signaing inhibitor 
compared to conventional anti-androgens because it inhibits AR nuclear translocation, 
DNA binding, and co-activator recruitment [10]. Both abiraterone acetate and 
enzalutaminde are administered sequentially or in combination wth DTX and 
unfortunately lead to a modest median of 4-5 month improvement in survival [10, 12]. In 
2012, the FDA expanded approval for abiraterone acetate use in patients who have not 
yet received chemotherapy [12].  
 
Glucocorticoid Receptor “Take-Over” Pathway 
Despite the initial success reported with abiraterone and enzalutamide treatment, 
after an average of 6-12 months, response is limited due to acquired resistance. Recent 
work has highlighted another mechanism by which patients become resistant to anti-
androgens, specifically enzalutamide [11, 17]. This pathway involves an increased 
expression of glucocorticoid receptor (GR) and a bypass of AR-target genes with 
evidence showing that GR can bind to over half of all AR binding sites [11]. GRs are 
nuclear receptors very similar in structure to AR. In addition, glucocorticoids initially 
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have a suppressive effect on PCa and are often given in combination with early CRPC 
treatments [11]. Because the DNA binding domain of the glucocorticoid receptor is 
similar to that of AR, its upregulation in patients treated with chemotherapy or ADT may 
contribute to enzalutamide resistance [11]. GR expression was found to be upregulated in 
these resistant tumors and implicated in substituting AR to activate a similar but 
distinguishable set of genes that was determined to be necessary for the maintenance of 
enzalutamide resistance [17]. These findings were critical in establishing a key 
mechanism detailing an escape from AR blockade through the selection of cells that are 
able to drive the expression of AR target genes via an alternative nuclear receptor [17].  
 
AR Splice Variants Contribute to CRPC 
There is a significant subset of patients receiving abiraterone acetate or 
enzalutamide who do not respond to either treatment; this is called innate or primary 
resistance. In addition, the vast majority of patients who do initially respond to these two 
drugs will eventually develop acquired or secondary resistance. Understanding the 
mechanisms involved in primary and secondary resistance is an area of recent focus, with 
the activity of AR splice variants (ARVs) being implicated as a putative resistance 
mechanism in CRPC [18]. ARVs are truncated versions of wild type AR that are 
considered constitutively active. The role of ARV expression in clinical CRPC is 
currently being established, with some groups showing that ARVs are associated with 
poorer prognosis, and others reporting higher levels of ARV expression in CRPC bone 
metastasis compared to hormone-sensitive PCa bone metastasis [11].  
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There are over 20 described ARVs, with the most abundant being the ARV7. 
ARV7 is clinically relevant, with detection in human clinical samples from patients with 
CRPC [18]. Secondly, ARV7 is also a constitutively active variant that is capable of 
stimulating transcription of AR genes in the absence of androgens and cannot be 
inhibited in vitro or in vivo by drugs that target the AR ligand-binding domain [18]. 
Thirdly, ARV7’s relevance is supported by the fact that its expression is increased 20-
fold in CRPC tissues compared to hormone-sensitive tissues [18]. Therefore, there is 
evidence for the use of ARV7 as a prognostic marker to either determine poor outcomes 
in patients with CRPC or as a treatment-selection marker that can provide additional 
prognostic information[18]. Before the overall contribution of ARV7 can be determined, 
however, further work needs to be done including testing the clinical utility of ARV7 in 
the context of other therapies (i.e. taxanes), validating assay performance, and validating 
the clinical relevance of ARV7 status in predicting response/resistance to treatment in a 
context-specific manner  [11, 18].  
 
Taxane Chemotherapy 
 DTX chemotherapy is the current standard of care for patients diagnosed with 
CRPC, based on the SWOG 9916 and TAX327 clinical trials, which demonstrated a 3-
month survival advantage of DTX over mitoxantrone [11, 14, 19]. DTX is an anti-mitotic 
chemotherapeutic agent that inhibits mitosis by stabilizing the microtubules and binding 
to the " subunit, preventing depolymerization and resulting in cell death. With the 
approval of abiraterone acetate and enzalutamide, DTX is often not the first line therapy 
of choice [11]. The CHAARTED trial compared DTX and ADT vs. ADT alone in 
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hormone-naïve Pca patients. This clinical trial demonstrated that DTX can be used as an 
initial treatment option for hormone-naïve patients since DTX in combination with ADT 
resulted in a 17-month survival advantage over ADT alone in patients with visceral 
metastases [11, 20]. The STAMPEDE trial showed similar results to CHAARTED with 
DTX in combination with ADT resulting in a 10-month survial benefit over ADT alone 
in men with high-risk locally advanced or metastatic PCa [11, 21]. Despite its 
effectiveness, all DTX-treated patients eventually develop resistance, and there are 
numerous mechanisms implicated in this acquired resistance [11, 15].  
 The taxane drug cabazitaxel (CTX) is a chemotherapeutic agent approved by the 
Food and Drug Administration (FDA) for use in patients with mCRPC who failed DTX 
chemotherapy. CTX was developed to have poor affinity for ABCB1 due to the role of 
this efflux pump in mediating DTX resistance [15, 22]. CTX was found to have a 2.4-
month survival benefit compared to mitoxantrone in patients with mCRPC who 
progressed with DTX treatment [11, 23]. As with DTX, patients treated with CTX also 
develop resistance and face disease progression [11, 15, 24] Therefore, there is a need for 
novel combinatorial therapies aimed at killing the tumors and circumventing resistance.  
 
Mechanisms of Taxane Chemoresistance  
Multidrug transporters 
 The mechanisms contributing to DTX-resistance are well-studied but poorly 
understood as evidenced by the fact that therapies aimed at targeting these pathways have 
failed clinically [11]. DTX-resistance has been linked to the activity of multidrug 
transporters that act as efflux pumps to reduce the intracellular concentrations of 
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chemotherapeutic agents [24, 25]. Multidrug transporters are membrane proteins 
belonging to the ATP-binding cassette (ABC) family of transporters. The most notable 
are ABCB1, MDR protein 1 (MRP1) or ABCC1, and breast cancer resistance protein 
(BCRP) or ABCG2 [11], all of which are associated with drug resistance [24].  
ABCB1 is weakly expressed in normal prostate but its expression increases as 
disease stage and tumor grade increase. It is also highly expressed in DTX-resistant PCa 
cells [24-26] and primary cancer cell cultures [24]. MRP1/ABCC1 and BCRP/ABCG2  
are both associated with a multi-drug resistant phenotype. Unlike ABCB1, ABCC1 is 
more readily expressed in DTX-sensitive PCa cell lines, but like ABCB1 its expression 
also correlates with advanced PCa and high Gleason score [24, 27]. ABCG2 has been 
shown to have a possible role in PCa progression with expression correlating with worse 
patient survival. In addition, phosphorylation of ABCG2 by the serine/threonine kinase 
Pim-1 mediates DTX-resistance in PCa cell lines [28]. Interestingly, ABCG2 is a well 
established universal and PCa stem cell marker [29], and its expression has been 
implicated in the innate chemoresistance observed in stem cells [24]. Preclinical data 
determining the role of multidrug transporters in chemotherapy resistance led to the 
development of CTX, designed to have low affinity for ABCB1 efflux [15, 24].  
 
Tubulin Isoforms 
Another mechanim assocated with DTX-resistance is the upregulation of class III 
"-tubulin isoforms which are common in DTX-resistant cancer cell lines and result in 
less stable microtubules [24]. Elevated "III-tubulin is correlated with poor response to 
tubulin-targeting agents and with poor prognosis in many human malignancies. In 
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addition, targeting of this isoform restores DTX sensitivity [30]. DTX-resistant cells have 
elevated expression of "III-tubulin, which is clinically associated with disease 
progression, tumor aggressiveness, and poor response to taxane therapy [30, 31]. 
Although this isoform has been well-characterized in DTX-resistant breast cancer, this 
mechanism of resistance has yet to be confirmed in PCa due to lack of metastatic biopsy 
samples of taxane-resistant tumors to specifically examine tubulin alterations. Further 
studies are required to determine the impact of these modifications in clinical decision-
making [31].  
 
Survival Pathways and Inflammatory Cytokines  
STAT-1 and STAT-3 
 The binding of DTX to "-tubulin induces a stress response that activates multiple 
survival pathways inducing c-JNK, STAT-1 and STAT-3, and NF-!B. STAT (signal 
transducer and activator of transcription) proteins are transcription factors that regulate 
gene expression and influence cell growth, differentiation, proliferation, and apoptosis 
[32]. When PC3 and DU145 mCRPC cells become resistant to DTX, STAT1-dependent 
clusterin (CLU) expression is upregulated [33]. CLU is an anti-apoptotic protein that is 
associated with PCa progression and chemoresistance [34]. STAT-3 expression is also 
implicated in DTX-resistance through the serine-threonine kinase PIM1, contributing to 
cell survival [35]. 
 
NF-!B 
Inflammation has long been established as a major driver in PCa carcinogenesis 
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and progression [36], and its role in DTX-resistance has been well-studied with several 
groups demonstrating inflammatory cytokine upregulation in mCRPC patients treated 
with DTX. NF-!B is found in the cytoplasm and is inhibited by I!B-#. When I!B 
kinases are stimulated, I!B-# is degraded and NF-!B is able to translocate to the nucleus 
and activate transcription of a wide array of genes that code for angiogenic factors, cell 
adhesion molecules, anti-apoptotic factors, and cytokines [32, 37]. These genes are 
thereby able to contribute to cell survival, invasion, metastasis, and chemoresistance [32].  
 
IL-6 and IL-8 Signaling 
Among the many targets of NF-!B are the genes that encode for Interleukin 6 (IL-
6) and Interleukin 8 (IL-8), two cytokines that stimulate PCa cell growth in an autocrine 
and paracrine manner and are involved in the development and progression of the disease 
[38-41]. Androgen-independent PC3 and DU145 PCa cells have elevated IL-6 and IL-8 
production in conditioned media due to NF-!B activity. This same observation does not 
occur in androgen-sensitive LNCaP PCa cells [38, 40]. PC3 and DU145 cells have higher 
NF-!B activity and secreted more IL-6, making them more resistant to DTX compared to 
LNCaP cells [42]. Pharmacological inhibition of NF-!B reduced IL-6 levels and 
increased the cytotoxic effects of DTX in PC3 and DU145 cells but not LNCaP cells 
[42]. This finding is supported clinically by a significant association in mCRPC PCa 
patients between high serum and tumor expression levels of IL-6 and decreased response 
to DTX treatment [37, 42]. High IL-6 and IL-8 production enhances proliferation and 
inhibits apoptosis in PC3 and DU145 cells [38, 40]. Through the JAK/STAT pathways, 
IL-6 and IL-8 are effectors of NF-!B activity in DTX-resistance [38, 40].  
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CCL2 
Chemokines, which function to induce chemotaxis in neighboring cells, have also 
been implicated in DTX-resistance. Most notable is the chemokine ligand 2 (CCL2), 
which is expressed in PCa cell lines and primary tumors and is correlated with malignant 
potential [43, 44]. CCL2 expression in mCRPC cell lines is increased by DTX treatment 
through the activation of JNK signaling resulting from DTX binding to microtubules 
[45]. In addition, CCL2 can act in an autocrine manner to promote cell survival and 
resistance to DTX through stimulation of Erk/MAP kinase and PI3K/AKT signaling 
pathways [46, 47].  
 
Chaperone Proteins 
Heat Shock Proteins 
Chaperone proteins have long been implicated in DTX-resistance, with heat shock 
proteins and CLU being the most notable and extensively studied [32]. Heat Shock 
Protein 27 (HSP27) and HSP90 are overexpressed in mCRPC cells and their expression 
increases as cells become DTX-resistant [48, 49]. In addition, targeting of these proteins 
in cellular models resulted in DTX resensitization [49, 50]. Unfortunately, however, 
clinical trials targeting HSP90 have yet to improve overall survival [32]. Clinical studies 
with HSP27 using the second generation antisense drug OGX-427 resulted in a decrease 
in circulating tumor cells in mCRPC patients [49]. Results from Phase I clinical trials in 
mCRPC patients using OGX-42 in combination with DTX have yet to be reported.  
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Clusterin 
CLU,  a chaperone protein, is upregulated in DTX-resistant PCa cells and is 
considered a key protein in mediating DTX-resistance in PCa [34]. CLU exists in two 
isoforms resulting from two distinct transcriptional start sites. They include a truncated 
nuclear form (nCLU) that promotes CRPC cell death [51],  and a secreted form (sCLU) 
that prevents cell death [52]. nCLU and sCLU are not produced simultaneously, and a 
shift from nCLU to sCLU production occurs during PCa progression [53]. Therefore, 
nCLU expression is not detected in prostate tumor cells and sCLU is overexpressed in 
DTX-resistant cells, with elevated expression levels correlating with DTX resistance 
[54]. sCLU in vitro knockdown with antisense oligonucleotide increases the sensitvity of 
resistant PCa cells [55].  
As previously mentioned, sCLU expression is induced by DTX through STAT-1 
activation in PC3 and DU145 cells. AKT inhibition suppressed CLU expression in DTX-
resistant CRPC cells and resensitized them to DTX,  showing that CLU expression is 
dependent on AKT activation of STAT-1 [56]. sCLU confers its anti-apoptotic effects in 
the cytoplasm of the cell by binding and stabilizing the Ku70-Bax complex preventing 
the release of Bax to the mitochondria to initiate cytochrome c release and thereby 
preventing caspase-9 and -3 dependent apoptosis [34, 57]. 
CLU is also regulated by transforming growth factor "1 (TGF-"1) [58]. TGF-"1 
is in turn upregulated by the transcription factors YB-1 and Twist 1 [58]. Through this 
upregulation, CLU contributes to epithelial-mesenchymal transition (EMT) and 
metastasis of PCa cells [58]. CLU reduction reduced TGF-"1induction of N-cadherin and 
fibronection, both markers of EMT, thereby inhibiting the migratory and invasive 
 17 
properties of TGF-"1 [58]. Targeting of CLU in an in vivo model also suppressed 
metastasis. These findings indicate that CLU is an important mediator of TGF-"1-
induced EMT, and CLU may be a promising target for reducing cancer metastasis [58].  
 
AR Splice Variants in the Context of Taxane Chemoresistance 
PCa is fundamentally AR-driven especially in the context of disease etiology and 
progression. Because the intraprostatic response of PCa cells to androgens depends on the 
expression and sensitivity of ARs, ADT has been a mainstay of PCa treatment and 
typically precedes taxane chemotherapy. As mentioned above, constitutively active 
ARVs have been shown to be overexpressed in mCRPC and confer resistance to ADT by 
inhibiting the nuclear translocation of the androgen-AR complex [59-62]. More recently, 
there has been a shift in focus to the role of AR in DTX-resistance in mCRPC patients 
with AR mutations. An initial study suggested that the presence of AR splice variants 
may affect sensitivity to taxane treatment and that tumors predominantly expressing 
ARV7 would likely be resistant to DTX [63].  
Since this initial report, a separate group has coordinated a replication study and 
their results refute the initial findings regarding ARV7 and DTX-resistance [64]. In 
addition, a separate group found that detection of ARV7 in circulating tumor cells of 
mCRPC patients was not associated with taxane-resistance, negating the clinical 
significance of ARV7 in patients receiving DTX [18]. Considering the inconsistency 
reported in the literature regarding AR-DTX interactions, studies exploring DTX-
resistance using cellular models must take into account the AR status of cell lines used to 
determine the most clinically relevant scenario for the question being addressed.  
 18 
LEDGF/p75 Promotes DTX-Resistance 
The Lens Epithelial Derived Growth Factor protein of 75 kDa (LEDGF/p75) is 
activated during cellular response to stress. It is a transcription co-activator with 
oncogenic function [65, 66] that specifically promotes cellular survival against 
environmental stressors such as oxidative stress, radiation, heat, serum starvation, and 
cytotoxic drugs [26, 65-70]. LEDGF/p75 has been shown to have a role in PCa and other 
cancers, contributing to resistance to various cytotoxic drugs, including DTX [26, 68, 70, 
71]. DTX-resistant PCa cell lines upregulate transcript and protein expression of 
LEDGF/75 compared to DTX-sensitive cells [26, 48, 71]. Our group has also 
demonstrated that siRNA-mediated knockdown of LEDGF/p75 is able to partially 
resensitize DTX-resistant cells to DTX therapy [26]. 
 
Epithelial to Mesemchymal Transition  
EMT occurs when there is a breakdown of cell-to-cell-to-extracellular matrix 
adherence to the epithelial lining [72], a process that facilitates cancer metastasis. E-
cadherin, a major component of epithelial adherence junction, functions to control EMT 
[72, 73]. Loss of E-cadherin is the hallmark step that signals the start of EMT [72]. 
Crucial mesenchymal markers include vimentin, N-cadherin, and E-cadherin 
transcriptional repressors including SNAI1 (Snail), SNAI2 (slug), TWIST1(Twist), 
ZEB1, and ZEB2; all of which contribute to enhanced cell mobility [72, 73].  
In our studies, Snail, Twist, vimentin, and N-cadherin were found elevated in the 
DTX-resistant PC3-DR and DU145-DR cells. Snail is a zinc-finger protein that binds to 
the E-cadherin promoter [72]. Snail is upregulated during enzalutamide resistance and is 
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highly expressed in metastatic PCa [72]. Snail’s role in facilitating metastasis involves 
the downregulation of tight junction proteins including zona occludin 1 [72]. Twist is a 
protein that plays critical roles during tumorigenesis also through the regulation of E-
cadherein expression [73]. Twist’s expression is significantly correlated with Gleason 
score and metastasis. Twist also functions to regulate N-cadherin expression by inducing 
transcriptional activation [73, 74]. Slug, another transcription factor, is regulated by AR 
signaling and contributes to the develepment of CRPC during ADT [73]. This evidence 
suggest that EMT contributes to drug resistance in PCa.  
The link between EMT and cancer stem cells (CSCs) in contributing to drug 
resistance in CRPC has recently been explored in various cancer types [73-76]. What is 
emerging from these studies is the hypothesis that characteristics of EMT are closely 
associated with signatures of CSCs, leading to the drug resistant phenotype. Evidence for 
this has been observed in breast and pancreatic cancer, where TGF", a potent EMT 
inducer, stimulated a marked increase of cells with a CSC phenotype and marker 
expression [73]. In addition, a study in breast cancer demonstrated that upregulation of 
Zeb1, an EMT regulator, was sufficient to switch cells from a non-cancer stem cell 
phenotype to a CSC status [76]. This link between EMT markers and CSC-like 
phenotype in DTX-resistance in CRPC is explored in this dissertation. 
 
Cancer Stem Cells 
PCa resistance to chemotherapy, the primary cause of treatment failure, is driven 
by the survival of subpopulations of prostate tumor cells that eventually contribute to 
aggressive disease progression, characterized by metastasis to the bone and vital organs 
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[77]. In addition, PCa tumors are highly heterogenous, with many areas containing 
genetically distinct clones [78], a characteristic that also contributes to therapy resistance 
and tumor relapse [77]. An emerging explanation for both the cellular heterogeneity and 
treatment resistance in PCa and other solid tumors is the CSC hypothesis, which states 
that solid tumors are organized heirarchically with only a small subset of cells capable of 
tumor-initiating and tumor-propagating capacity [77, 79].  
CSCs are defined by their capacity for self-renewal, potential to differentiate into 
any cell-type within a tumor, and proliferative capacity to drive the establishment of a 
tumor. The ability to expand or repopulate a bulk tumor is the result of aggressive 
metastatic activity, and increased resistance to chemotherapy and radiotherapy [79]. The 
CSC theory establishes that stem-like cells maintain the tumor population. Recent studies 
suggest that cancer cells can de-differentiate into CSCs under certain tumor 
microenvironmental conditions [79, 80]. This phenomenon is referred to as plasticity [79, 
80].  
Chemotherapeutic drugs, like DTX, have cytotoxic effects on the bulk tumor, but 
due to the presence of CSCs, these effects are temporary since this small cell population 
employs multiple redundant mechanisms that facilitate cell survival. In addition, the non-
proliferative state of CSCs allows them to exist as cellular reserves facilitating an 
environment where a small population of cells can persist after anti-proliferative 
treatments repopulate the tumor and/or metastasize [77]. Recently the emerging role of 
CSCs in the acquisition of PCa chemoresistance has been explored and partially 
characterized [75, 77, 81, 82]. CSCs employ many of the same resistance mechanisms 
previously mentioned but at an enhanced level, including increased activity of drug-
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efflux pumps, heightened DNA repair efficiency, and increased detoxification enzyme 
expression; but unlike other cells, they employ quiescence [83]. Quiescence is of 
particular concern when considering that the mechanism-of-action of many cytotoxic 
drugs depends on the propensity of cancerous cells to be metabolically active and rapidly 
dividing.  
CSCs are typically identified based on the presence and/or absence of several cell 
surface markers, the combination of which is specific for the CSC phenotype identified in 
a particular tumor type. Markers for PCa stem cells include cell surface proteins such as 
CD44, CD133, CD117, ABC transporters (ABCB1, ABCG2), cytoplasmic proteins such 
as NES, enhanced aldehyde dehydrogenase (ALDH) activity, and nuclear proteins such 
as Sox-2, Oct 3/4, and Nanog [84]. Table 1 highlights the validated CSC markers utilized 
in PCa studies.  
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Table 1. Putative prostate CSC Makers Identified in PCa Cell Lines, Animal Xenografts 
and Human Primary PCa Tissues.  
From Ni J et al., 2014 [79] 
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Therapies Targeting CSC pathways 
Current targeting of CSCs focuses on the signaling pathways upregulated in stem 
cells that are specific to their function. These pathways include Hedgehog, Wnt, Notch, 
and NFkB pathways. The Hedgehog (Hh) pathway plays an important role in regulating 
CSCs in PCa by regulating target genes involved in proliferation, survival, and metastasis 
[85].This pathway also promotes chemoresistance by increasing transcription of ABCB1 
and ABCG2 in PCa [85]. Hh inhibitors have shown promise in vitro with numerous 
clinical trials currently testing inhibitors for PCa treatment [77].  
Wnt signaling contributes to CSC development, making it a promising target. As 
with the Hh pathway, many therapeutic agents targeting Wnt are under clinical study 
including monoclonal antibodies against the Wnt cascade and a small molecule inhibitor 
that has been shown to inhibit PCa tumor growth in vitro [77].  
Notch signaling is overactivated in PCa and its silencing is predicted to inhibit 
tumor growth and differentiation [86, 87]. Many phamacological agents targeting Notch 
signaling are undergoing clinical study including siRNAs, and monoclonal antibodies 
against Notch receptors and/or ligands. GSI, a gamma-secretase inhibitor, is being 
combined with bicalutamide in patients whose PCa recurs after surgery or radiation [87].  
Many challenges exist with targeting CSCs, many of which involve the lack of 
understanding of the underlying pathways and the genetic alterations that maintain or 
create CSC-niches in the tumors. For example, targeting the biomarkers that identify 
prostate CSCs and signaling pathways that sustain this population are potential targets for 
novel drug development alone or in combination [79]. However, there remains a need to 
better understand where CSCs originate and how they develop and are sustained. As with 
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other cancers, prostate CSCs are phenotypically and functionally diverse [79], therefore, 
understanding the relationship between distinct CSC populations is important to develop 
strategies to target them.  
 
Therapies to Circumvent DTX-Resistance   
The main goal of novel therapies for mCRPC are to either bypass DTX-resistance 
using an alternative/redundant anti-tumoral pathway or to directly inhibit the pathways 
directly causing resistance. Anti-tumoral approaches worth mentioning include 
Sipuleucel-T, abiraterone acetate, enzalutamide, and alpharadin. Sipuleucel-T is an 
immunotherapy approved in 2010 by the FDA. This anti-tumor vaccine resulted in a 4.1 
month improvement in median overall survival compared to placebo group [88]. Lastly, 
the radiopharmaceutical alpharadin radium-223 chloride was found to be effective in 
patients with CRPC and mCRPC with no differences found with previous DTX usage 
[89]. Despite the increased survival reported for each new treatment, effectiveness is 
limited.  
The number of therapies available to overcome development of DTX-resistance 
are far less numerous [32]. Only two are FDA approved for use in CRPC, including CTX 
and denosumab. As previously mentioned, CTX is a DTX-related taxane that was 
developed to limit drug efflux and thereby make it more effective [11]. Denosumab is an 
antibody targeted against the receptor activator of nuclear factor !B ligand (RANK-L). 
This treatment was developed to inhibit the NF!B survival pathway, which is activated 
by taxane therapy [32].  
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Many promising treatments developed to circumvent DTX-resistance pathways 
have failed to show success in the clinical setting. Of importance is OGX-011 or 
Custirsen, a next generation oligonucleotide targeting sCLU. Despite initial sucess in 
preclinical models and Phase I and II studies, Custirsen in combination with DTX or 
CTX failed to show any benefit over chemotherapy alone in Phase III studies [90, 91], 
with the SYNERGY trial reporting 5% adverse effects in the DTX, prednisone, and 
Custirsen group leading to patient death [91]. Another promising treatment was the IL-6 
monoclononal antibody siltuximab (CNTO 328). This Phase II study involved siltuximab 
treatment in combination with mitoxantrone compared to mitoxantrone alone. 
Unfortunately,  the study did not meet its primary endpoint and resulted in no apparent 
improvement in survival outcomes [92].  
 
RNA Sequencing as an Approach to Transcriptome Profiling 
Next generation sequencing (NGS) has revolutionized transcriptomics by making 
it feasible to analyze expressed genes from any tissue or species without needing to 
identify known transcripts. This is significant because previous global RNA analysis was 
restricted only to known splice variants or nucleotide sequences. RNA sequencing (RNA-
seq) is a more sensitive technique compared to microarrays, with a longer range and the 
ability to determine allele-specific expression making it the current preferred method of 
large-scale RNA studies. Unfortunately, the data produced from these studies is dense 
and complex, requiring significant time commitments to mine the data sets and 
extrapolate the results [93]. 
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Hypothesis and Purpose of Dissertation Work 
Understanding the molecular mechanisms underlying the acquisition of PCa 
chemoresistance is critical for developing novel combinatorial therapies for the 
prevention or reversal of taxane-resistance, which will improve patient survival and 
ultimately result in a curative option for mCRPC. Several mechanisms involved in the 
acquisition of DTX-resistance have been identified, including the role of multidrug 
resistance pumps (e.g. ABCB1), impaired apoptotic pathways (e.g. Bcl-2), cytokine and 
chemokine induction (e.g. IL-6, CCL2), alterations in microtubule structure and function, 
NF-kB pathway activation, and upregulation of stress proteins (e.g. Hsp27, clusterin, and 
LEDGF/p75) [11, 26, 31, 32]. 
  Unfortunately, efforts aimed at targeting or disrupting some of these pathways in 
the clinical setting have been largely unsuccessful [13]. This is illustrated by the recent 
failure of  phase III clinical trials with Custirsen [90, 91]. Such failures highlight the 
importance of continued efforts towards discovering new mechanisms and molecular 
pathways associated with the taxane-resistant phenotype. Given the scarcity of genomic 
studies examining the transcriptomic programs activated during development of DTX-
resistance in mCRPC, we performed RNA-seq on DTX-sensitive and DTX-resistant 
mCRPC cells in an effort to identify new gene pathways potentially involved in taxane 
resistance. Due to the inconsistency in the literature regarding AR-DTX interactions [63, 
64], we chose not to focus on the role of AR in DTX and avoided the use of AR-positive 
cell lines. As such, PC3 and DU145 are AR-negative CRPC cell lines which are often 
used for DTX-resistance studies, and were deliberately chosen as cellular models for the 
purposes of this study.  
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 We hypothesized that the RNA sequencing will reveal differentially expressed 
upregulated and downregulated genes when cells transition from DTX-sensitivity to 
DTX-resistance. The goal of the present study is to identify new therapeutic targets that 
are critical for the acquisition of DTX-resistance. This will lead to the development of 
new therapies to halt the progression of advanced PCa, resulting in a cure for this 
malignancy.  
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Abstract 
 Patients with metastatic castration-resistant prostate cancer (mCRPC) develop 
resistance to conventional therapies including docetaxel (DTX). Identifying molecular 
pathways underlying DTX resistance is critical for developing novel combinatorial 
therapies to prevent or reverse this resistance. To identify transcriptomic signatures 
associated with acquisition of chemoresistance we profiled gene expression in DTX-
sensitive and -resistant mCRPC cells using RNA sequencing (RNA-seq). PC3 and 
DU145 cells were selected for DTX resistance and this phenotype was validated by 
immunoblotting using DTX resistance markers (e.g. clusterin, ABCB1/P-gp, and 
LEDGF/p75). Overlapping genes differentially regulated in the DTX-sensitive and -
resistant cells were ranked by Gene Set Enrichment Analysis (GSEA) and validated to 
correlate transcript with protein expression. GSEA revealed that genes associated with 
cancer stem cells (CSC) (e.g., NES, TSPAN8, DPPP, DNAJC12, and MYC) were highly 
ranked and comprised 70% of the top 25 genes differentially upregulated in the DTX-
resistant cells. Established markers of epithelial-to-mesenchymal transition (EMT) and 
CSCs were used to evaluate the stemness of adherent DTX-resistant cells (2D cultures) 
and tumorspheres (3D cultures). Increased formation and frequency of cells expressing 
CSC markers were detected in DTX-resistant cells. DU145-DR cells showed a 2-fold 
increase in tumorsphere formation and increased DTX resistance compared to DU145-
DR 2D cultures. These results demonstrate the induction of a transcriptomic program 
associated with stemness in mCRPC cells selected for DTX resistance, and strengthen the 
emerging body of evidence implicating CSCs in this process. In addition, they provide 
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additional candidate genes and molecular pathways for potential therapeutic targeting to 
overcome DTX resistance.  
 
Introduction 
Prostate cancer (PCa) is the most commonly diagnosed cancer and the second 
cause of cancer deaths among American men [1]. For men diagnosed with advanced PCa, 
treatment with curative intent is no longer an option, and androgen deprivation therapy 
(ADT) remains the main therapeutic modality [2, 3]. Despite its initial effectiveness at 
reducing tumor growth, ADT ultimately fails, resulting in metastatic castration-resistant 
prostate cancer (mCRPC), a lethal stage of the disease that is marked by recurrence of 
elevated prostate specific antigen (PSA) and progression of metastatic lesions [3, 4]. 
Since 2004, the standard first-line chemotherapeutic agent for the treatment of mCRPC 
has been the taxane drug docetaxel (DTX), a microtubule-stabilizing agent that 
moderately increases overall survival [4, 5]. Eventually, however, chemoresistance 
occurs in all DTX-treated patients resulting in continued disease progression [6]. In 
recent years, new treatment options for mCRPC have been developed, including the next-
generation androgen receptor-targeting agents abiraterone acetate and enzalutamide, 
therapeutic vaccines, and the second generation taxane cabazitaxel [6, 7]. Unfortunately, 
these novel therapeutic agents, which are often administered sequentially or in 
combination with DTX, only moderately improve overall patient survival due to the 
development of therapy resistance. 
Understanding the molecular mechanisms underlying the acquisition of PCa 
chemoresistance is critical for developing novel and effective combinatorial therapies for 
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the prevention or reversal of taxane resistance. Several mechanisms involved in the 
development of DTX-resistance have been identified, including the increased expression 
and activity of multidrug resistance pumps (e.g. ABCB1/P-gp/MDR1), impaired 
apoptotic pathways (e.g. Bcl-2), cytokine and chemokine induction (e.g. IL-6, CCL2), 
alterations in microtubule structure and function, NF-kB pathway activation, and 
upregulation of stress survival proteins (e.g. Hsp27, clusterin, and LEDGF/p75) [2, 8, 9]. 
Unfortunately, efforts aimed at targeting or disrupting some of these pathways in the 
clinical setting have been largely unsuccessful [4]. This is illustrated by the recent failure 
of phase III clinical trials with Custirsen, a second generation oligonucleotide 
administered in combination with DTX designed to disrupt the production of clusterin 
(CLU), a cytoprotective anti-apoptotic chaperone protein overexpressed in PCa [10, 11]. 
Such failures highlight the importance of continued efforts towards discovering new 
mechanisms and molecular pathways associated with the taxane-resistant phenotype.  
Chemoresistance, the primary cause of treatment failure, is driven by the survival 
of subpopulations of prostate tumor cells that eventually contribute to aggressive disease 
progression, characterized by metastasis to the bone and vital organs [12]. In addition, 
PCa tumors are highly heterogeneous, with many areas containing genetically distinct 
clones [13], a characteristic that also contributes to therapy resistance and tumor relapse 
[12]. An emerging explanation for both the development of resistance and the cellular 
heterogeneity in PCa and other solid tumors is the cancer stem cell (CSC) hypothesis, 
which proposes that solid tumors are organized hierachically with only a minor subset of 
cells capable of tumor-initiating and tumor-propagating capacity [12, 14].  
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Recent studies revealed that markers associated with epithelial-to-mesenchymal 
(EMT) transition and CSCs are elevated in DTX-resistant mCRPC cells [15, 16], and that 
CSCs derived from immortalized normal prostate epithelial cells showed increased DTX 
resistance compared to parental adherent cells [17]. Given the scarcity of next generation 
sequencing (NGS) studies examining the transcriptomic programs activated during 
development of DTX-resistance in mCRPC, we performed an RNA sequencing (RNA-
seq) analysis on DTX-sensitive and DTX-resistant mCRPC cells in an effort to identify 
gene pathways potentially involved in taxane resistance. GSEA analysis of the 
overlapping upregulated genes in DTX-resistant PC3-DR and DU145-DR cells revealed 
an induction of a transcriptomic program associated with stemness as cells transitioned 
from DTX sensitivity to resistance. To validate this finding, we characterized the CSC 
phenotype in tumorspheres from DTX-resistant PC3-DR and DU145-DR cells using CSC 
markers previously validated in prostate tumorspheres. Understanding the role of CSCs in 
PCa chemoresistance, including the transcriptomic pathways that define their activation 
and maintenance is critical to identifying new targets for combinatorial therapies aimed at 
circumventing taxane resistance in mCRPC.  
 
Results 
PC3-DR and DU145-DR Cells Upregulate Markers of Taxane Resistance 
We developed PC3-DR and DU145-DR cell lines by selecting and expanding the 
surviving cells in the presence of incrementally increasing concentrations of DTX until 
cells could be maintained in 10 nM DTX with minimal cell death [8, 18]. Our group 
reported recently that these DTX-resistant cell lines are also resistant to paclitaxel and 
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cabazitaxel, other clinically relevant taxanes [8]. We also demonstrated that these DTX-
resistant cells overexpress the stress oncoprotein Lens Epithelium Derived Growth Factor 
of 75 kD (LEDGF/p75), and that depletion of this protein partially resensitized these cells 
to DTX [8, 18]. In the present study, we confirmed that the DTX-resistant PC3-DR and 
DU145-DR cell lines used in the RNA-seq analysis and other experiments displayed 
significant upregulation of proteins previously implicated by our group and others in PCa 
progression and DTX resistance [8, 9, 19-23] including LEDGF/p75, CLU, and ATP-
binding cassette sub-family B member 1 (ABCB1), compared to the sensitive cells 
(Figure 2A-2C). This validation step was critical prior to initiating our RNA-seq analysis 
comparing the transcriptome profiles of DTX-sensitive and DTX-resistant PCa cell lines.  
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Figure 2. DTX-resistant PC3 and DU145 Cell Lines Upregulate Known Markers of 
DTX Resistance. Upper panel: Western blots of (A) LEDGF/p75, (B) CLU, and (C) 
ABCB1 showing upregulation of these proteins in DTX-resistant PC3 and DU145 
mCRPC cells, compared to the parental, sensitive cells. Bottom panel: quantification 
of fold change in protein expression (A n=8, B n=5, C n=4 independent experiments). 
*P<0.05; **P < 0.05; ***P < 0.001. Due to the absence of ABCB1 expression in the 
parental PC3 and DU145 cells, for quantification purposes we normalized its 
expression in these cells to an arbitrary value of 0.10. Error bars represent mean   
standard deviation (SD). 
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RNA-seq Analysis Revealed Upregulation of Genes Associated with CSC-like 
Characteristics 
Principal Component Analysis (PCA) 3D mapping of our RNA-seq data 
demonstrated that the DTX-sensitive PC3 and DU145 cells were clearly separated from 
each other based on global transcriptome expression profiles (Figure 3A). However, once 
these cell lines became DTX-resistant they were clustered together spatially, suggesting 
an acquired similarity in transcriptomic profiles. Global gene heat map also demonstrated 
the clustering of the DTX-resistant cell lines based on their transcriptome expression 
profiles (Figure 4). Our RNA-seq data revealed that of 31,864 total genes detected, 3,754 
and 2,552 were differentially upregulated with statistical significance (FDR > 0.05, and 
fold change [FC] > 2) in the DU145-DR and PC3-DR cells, respectively, compared to 
their DTX-sensitive counterparts (Figure 3B, 3C). Of these genes, 1,254 overlapped 
between the PC3-DR and DU145-DR cells. GSEA of the top 25 ranked overlap genes 
between the DTX-sensitive and DTX-resistant PC3 and DU145 cells revealed a distinct 
on/off switch of genes, suggesting a pattern of upregulated/downregulated genes 
associated with the development of DTX-resistance in both cell lines (Figure 3D) (see 
Figure 5 for top 50 ranked genes). An exhaustive PubMed literature search also revealed 
that 17 of the top 25 (70%) ranked overlapping genes upregulated in the DTX-resistant 
cell lines have been shown to be associated with or contribute to a CSC phenotype (Table 
2). Top downregulated genes are listed in Table 3. 
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Figure 3. Gene Expression Profiling Analysis Reveals Upregulation of CSC-associated 
Genes. (A) Principal component Analysis (PCA) mapping demonstrates clustering of 
DTX-resistant cell lines based on gene expression profiles. (B) Diagram showing the 
distribution of statistically significant differentially regulated genes in each cell line, 
comparing DTX-resistant (DR) to sensitive (S). (C) Diagram demonstrating the overlap 
or shared genes common to both PC3 and DU145 cells, comparing DR to S. (D) Heatmap 
of the top ranked genes generated using GSEA analysis on the common overlap genes 
between both sensitive PC3 and DU145 cells compared to PC3-DR and DU145-DR. Red 
represents fold upregulation and blue represents fold downregulation. (E) GSEA gene set 
pathway analysis revealed one pathway to be significantly enriched in the DTX-resistant 
PC3-DR and DU145-DR cells compared to sensitive PC3 and DU145 cells (P= 0.032) 
involving precursor metabolites and energy. A positive value indicates correlation with 
the sensitive phenotype and negative value indicates correlation with the resistant 
phenotype. 
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Figure 4: Hierarchical Clustering Heat Map of Global Gene Analysis 
for all Cell Lines (PC3, DU145, PC3-DR, and DU145-DR).  
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Fig 1: heat_map    Fig 1: heat_map    i       
 
 
Figure 5. GSEA Generated Heat Map of the Top-ranked 50 Overlap Genes. 
Significantly downregulated (blue) or upregulated (red) between DTX-sensitive PC3 
and DU145 compared to DTX-resistant PC3-DR and DU145-DR cells. 
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Table 2. GSEA Top-ranked RNA-seq Upregulated Genes 
 
!
Gene!
Name!
!
Gene!Title!
Rank!
Score!
(GSEA)!
Log2!Fold!
Change!
PC3!vs.!
PC3BDR!
Log2!Fold!
Change!
DU145!vs.!
DU145BDR!
!
Stem!CellB
Associated!
TSPAN8' tetraspanin'8' 04.782' 5.357' 5.815' YES'
'
MYC' v0myc'myelocytomatosis'viral'oncogene'homolog'
'
04.497'
'
3.813'
'
4.727'
'
YES'
'
DNAJC12' DNAJ'(Hsp40)'homolog,'subfamily'C,'member'12'
'
04.466'
'
4.411'
'
6.032'
'
YES'
F2R' coagulation'factor'II'(thrombin)'
receptor'
04.429' 4.289' 3.820' YES 
GLB1L2' galactosidase'beta'10like'2' 04.206' 3.421' 3.670' YES 
PLD6' phospholipase'D'family'member'6' 04.194' 3.537' 3.529' YES 
'
DPP4' dipeptidyl0peptidase'4'(CD26,'adenosine'deaminase'complexing'
protein'2)'
'
04.135'
'
3.890'
'
4.956'
'
YES 
FAM102B' family'with'sequence'similarity'102,'
member'B'
03.967' 3.196' 3.083' YES 
'
ST6GAL1' ST6'beta0galactosamide'alpha02,60sialyltransferase'1'
'
03.909'
'
2.925'
'
1.439'
'
YES 
'
CD55' CD55'molecule,'decay'accelerating'factor'for'complement'(Cromer'blood'
group)'
'
03.908'
'
2.652'
'
3.861'
'
YES 
HSF1' heat'shock'transcription'factor'1' 03.885' 3.083' 3.990' YES 
NES' nestin' 03.806' 3.477' 5.980' YES 
ZNF503' zinc'finger'protein'503' 03.725' 2.409' 3.432' YES 
CTGF' connective'tissue'growth'factor' 03.685' 2.779' 2.695' YES 
PMP22' peripheral'myelin'protein'22' 03.641' 2.798' 2.597' YES 
WDR25' WD'repeat'domain'25' 03.633' 2.690' 2.673' 0'
CCDC50' coiled0coil'domain'containing'50' 03.622' 2.355' 2.989' 0'
'
FABP5' fatty'acid'binding'protein'5'(psoriasis0associated)'
'
03.591'
'
2.538'
'
4.071'
'
YES'
FLVCR2' feline'leukemia'virus'subgroup'C'
receptor'2'
03.586' 2.460' 3.167' 0'
SMAGP' small'cell'adhesion'glycoprotein' 03.579' 2.538' 3.345' 0'
MROH1' maestro'heat0like'repeat'family'
member'1'
03.548' 2.535' 3.679' 0'
MAF1' MAF1'homolog'(S.'cerevisiae)' 03.501' 2.470' 3.158' 0'
CLGN' calmegin' 03.455' 2.784' 2.488' YES 
KLF4' kruppel0like'factor'4'(gut)' 03.452' 2.271' 2.657' YES 
ACOX2' acyl0coenzyme'A'oxidase'2,'
branched'chain'
03.437' 2.552' 2.371' 0'
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Table 3. GSEA Top 25-ranked RNA-seq Downregulated Genes 
 
!
Gene!
Name!
!
Gene!Title!
Rank!
Score!
(GSEA)!
Log2!Fold!
Change!PC3!
vs.!PC3BDR!
Log2!Fold!
Change!
DU145!vs.!
DU145BDR!
KRT7' keratin'7' 4.702' 07.497' 07.843'
HLA0C' major'histocompatibility'complex,'class'I,'C' 4.500' 05.337' 04.225'
LAMA3' laminin,'alpha'3' 4.494' 04.056' 04.376'
PLA2G16' phospholipase'A2'Group'XVI' 4.332' 03.905' 04.489'
'
ERBB2'
v0erb0b2'erythroblastic'leukemia'viral'oncogene'
homolog'2,'neuro/glioblastoma'derived'
oncogene'homolog'(avian)'
'
4.267'
'
03.339'
'
03.632'
AIFM2' apoptosis'inducing'factor,'mitochondria'
associated'2'
4.193' 04.127' 03.373'
C1ORF116' chromosome'1'open'reading'frame'116' 4.157' 03.317' 03.529'
'
PSMB8'
proteasome'subunit'beta'type,'8'(large'
multifunctional'peptidase'7)'
'
4.133'
'
06.159'
'
03.699'
JUP' junction'plakoglobin'' 4.100' 04.461' 03.666'
FURIN' furin'(paired'basic'amino'acid'cleaving'
enzyme)'
4.059' 03.102' 03.391'
ALS2CL' ALS2'C0terminal'like' 4.032' 03.975' 03.194'
LAM83' laminin,'beta'3' 3.984' 03.587' 04.206'
'
PKIG'
protein'kinase'(cAMP0dependent,'catalytic'
inhibitor'gamma'
'
3.963'
'
03.214'
'
02.976'
'
SEMA3C'
sema'domain,'immunoglobin'domain'(Ig),'short'
basic'domain,'secreted,'(semaphorin)'3C'
'
3.939'
'
02.957'
'
03.166'
MROH6' maestro'heat0like'repeat'family'member'6' 3.906' 04.171' 02.881'
TNS3' tensin'3' 3.858' 02.992' 02.889'
LY6E' lymphocyte'antigen'6'complex,'locus'E' 3.834' 03.344' 02.945'
SSH3' slingshot'homolog'3'(Drosophila)' 3.801' 02.733' 02.984'
PTPRF' protein'tyrosine'phosphatase,'receptor'type,'F' 3.765' 02.463' 03.473'
'
WNT7B'
wingless0type'MMTV'integration'site'family,'
member'7B'
'
3.686'
'
02.694'
'
04.630'
PTK28' PTK2B'protein'tyrosine'kinase'2'beta' 3.632' 03.658' 03.552'
CAPN5' calpain'5' 3.614' 02.852' 02.380'
'
SLC27A3'
solute'carrier'family'27'(fatty'acid'transporter),'
member'3'
'
3.592'
'
03.285'
'
02.310'
'
MICAL2'
microtubule'associated'monoxygenase,'
calponin'and'LIM'domain'containing'2'
'
3.590'
'
02.301'
'
02.910'
GCA' grancalcin,'EF0hand'calcium'binding'protein' 3.575' 03.679' 02.472'
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Gene Set Enrichment Analysis (GSEA) also identified the gene set 
“GO_Generation of Precursor Metabolites and Energy” as the only significantly enriched 
pathway in the DTX-resistant PC3-DR and DU145-DR cells (P = 0.032) (Figure 3E). 
This analysis yielded 8 genes (NADUFAF2, ENPP1, NDUFAB1, NDUFA8, PFKM, 
GNPDA1, CYC1, MYC) that were positive for core enrichment in this gene set. Of these 
genes, ectonucleotide phosphodiesterase 1 (ENPP1), cytochrome c-1 (CYC1), NADH 
dehydrogenase 1 alpha/beta subcomplex 1 (NADUFAB1), and v-myc myelocytomatosis 
viral oncogene homolog (MYC) have been associated with stem cell maintenance, 
phenotype acquisition, or reprogramming [24-29], suggesting that upregulation of 
specific genes involved in metabolism may contribute to an enrichment of cells with 
CSC-like characteristics (Figure 3E). Taken together, the RNA-seq analysis of transcript 
expression in DTX-sensitive vs. DTX-resistant PCa cell lines provides evidence for the 
acquisition of a transcriptomic program associated with stemness as a mechanism 
contributing to the development of DTX-resistance.  
 
Validation of Transcript and Protein Expression of Selected Genes in DTX-resistant 
Cells Confirmed RNA-seq Results 
To confirm the RNA-seq data, we performed in-house qPCR validation on 
selected genes that showed robust upregulation in both PC3-DR and DU145-DR cells, 
compared to the sensitive, parental cell lines. The selection of specific genes for 
validation was determined by two criteria: the GSEA ranked gene order (Table 2 and 
Table 3), and exhaustive literature searches implicating these genes in cancer, PCa, 
therapy resistance, DTX resistance, stem cells, CSCs, or EMT. For our in-house 
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validation of RNA-seq data, new RNA samples were extracted from a different set of 
DTX-sensitive and DTX-resistant cells than those used for the RNA-seq analysis. 
Consistent with the RNA-seq results, transcript expression of dipeptidyl peptidase 4 
(DPP4), tetraspanin 8 (TSPAN8), nestin (NES), DNAJ heath shock protein family 
member C12 (DNAJC12), fatty acid binding protein 5 (FABP5), and block of 
proliferation 1 (BOP1) were upregulated in PC3-DR and DU145-DR cells compared to 
the corresponding sensitive cell lines (Figure 6). As an internal control for in-house 
validation, we also chose two genes found robustly downregulated in the RNA-seq 
results, transglutaminase 2 (TGM2) and ATP-binding cassette subfamily C member 3 
(ABCC3). Transcript expression of both genes was robustly downregulated in PC3-DR 
and DU145-DR cells compared to the sensitive cell lines, further confirming the RNA-
seq results (Figure 6). The magnitude of fold-increase observed for each of these genes 
was more robust in DU145-DR cells than in PC3-DR cells, suggesting cell-type 
dependent differences in gene expression during the acquisition of resistance to DTX. 
Despite these differences, P values were consistently < 0.01 for each of the selected 
genes in both DTX-resistant cell lines.  
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Figure 6. In-house qPCR Validation of the Expression of Selected Top-ranked Genes 
from RNA-seq Results in DTX-Sensitive and DTX–Resistant mCRPC cells. qPCR 
validation for selected genes in (A) PC3 vs. PC3-DR and (B) DU145 vs. DU145-DR 
cells. White bars represent parental PC3 or DU145 and colored bars represent PC3-DR 
or DU145-DR. *P <0.05; **P < 0.05; ***P < 0.001. All RNA samples were analyzed 
in at least three independent experiments using at least three biological replicates per 
experiment. Error bars represent mean   SD. 
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After validation of the transcript expression of selected genes in the DTX-
resistant PC3-DR and DU145-DR cells, we sought to confirm corresponding protein 
upregulation in these cells compared to their sensitive counterparts by immunoblotting 
using specific antibodies. Significant upregulation of DPP4, TSPAN8, NES, DNAJC12, 
FABP5, and BOP1 was observed in the PC3-DR and DU145-DR cells, consistent with 
the qPCR and RNA-seq results (Figure 7A-7F). Also consistent with the RNA-seq and 
qPCR results, the protein expression of TGM2 was downregulated in the DTX-resistant 
cells (Figure 7G).  
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Figure 7. Protein Expression Validation of RNA-seq Results in DTX-sensitive and DTX-
resistant mCRPC Cells. Representative Western blot images and protein fold change 
quantification are shown for (A) DPP4 (n= 3), (B) TSPAN8 (n= 4), (C) NES (n= 6), (D) 
DNAJC12 (n= 4), (E) FABP5 (n= 7), (F) BOP1 (n=4), and (G) TGM2 (n=4). *P< 0.05; 
**P< 0.05; ***P< 0.001. All proteins were analyzed in at least three independent 
experiments. Error bars represent mean ± SD. 
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Analysis of Cancer Gene Microarray Datasets Reveals Consistent Upregulation of 
DNAJC12, FABP5, and BOP1 in PCa Tissues 
After confirming that transcript and protein expression of selected genes reflected 
the upregulation observed in the RNA-seq analysis, we sought to examine the expression 
of these genes in human PCa tissues. Transcript expression of the selected genes in PCa 
tissues, compared to normal prostate tissue, was analyzed using 16 PCa gene expression 
microarray datasets from the Oncomine database. All 16 datasets had data for FABP5, 
whereas data for DPP4 and TSPAN8 were available in 15 datasets, and data for BOP1, 
DNAJC12 and NES were available in 14, 10 and 8 datasets, respectively.  
Of the selected genes, DNAJC12, FABP5, and BOP1 were the most consistently 
upregulated in prostate tumors compared to normal prostate tissues in the dataset 
collection (Figure 8A-8C), with significant upregulation of DNAJC12 in 6 of the 14 
datasets (Figure 8A), FABP5 in 14 of the 16 data sets (Figure 8B), and BOP1 in 7 of the 
14 datasets (Figure 8C). DPP4 and TSPAN8 transcripts were significantly upregulated 
only in 4 of the 14 datasets (Figure 8D-8E). Interestingly, significant upregulation of 
NES transcript was detected only in 1 of the 8 datasets (Figure 8F). The magnitude of the 
fold-increase observed for the individual genes was modest, with only FABP5 showing 
over 2-fold increase in multiple datasets. However, the P values were <0.01 for most of 
the DNAJC12, FABP5, and BOP1 datasets, indicating that upregulation of these 
transcripts is highly significant in PCa tissues compared to normal tissues. On the other 
hand, NES transcripts were significantly downregulated in 4 of the 8 datasets, whereas 
DPP4 and TSPAN8 transcripts displayed significant downregulation in 1 and 2 out of 15 
datasets, respectively.  
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Figure 8. Expression of Selected Top-Ranked Genes in Clinical PCa Tissues. Fold 
change between transcript expression levels of selected top ranked genes (from RNA-seq 
analysis) in prostate tumors versus normal prostate tissues as derived from cancer gene 
microarray datasets in the Oncomine database. Individual dataset names appear in the 
legend box at the right. P values for the differences in gene expression between PCa and 
normal prostate tissues were obtained from Oncomine. The number of samples in each 
dataset is different, therefore higher fold change does not always correspond to statistical 
significance. *P< 0.05, **P< 0.01, ***P< 0.001. 
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PC3-DR and DU145-DR Cells Upregulate Markers Associated with EMT and CSCs 
The observation that highly ranked genes (GSEA) in the RNA-seq results were 
associated with CSC development or are known markers of CSCs (e.g. NES, DPP4, 
TSPAN8), led us to assess the expression of established EMT and CSC markers in our 
DTX-resistant cell lines. Microscopic assessment of DTX-resistant cells revealed a 
mesenchymal phenotype with clearly defined edges and the classical spindle-shaped 
morphology, compared to the flattened, polygonal-shaped sensitive PC3 and DU145 
(Figure 9A). Using multicolor flow cytometry, we analyzed the following populations in 
both DTX-sensitive and DTX-resistant cells: E-cadherin positive and N-cadherin positive 
(Figure 9B, 9C), as well as CD44+ and CD44+/ CD24- (Figure 10A, 10B). Consistent 
with their mesenchymal phenotype, DTX-resistant cells showed significantly reduced E-
cadherin expression compared to DTX-sensitive cells, concomitant with an increase in N-
cadherin expression, as determined by flow cytometry (Figure 9B, 9C) and 
immunoblotting (Figure 9D, left two panels). Notably, loss or downregulation of E-
cadherin is associated with poor prognosis in PCa [16]. We also observed that loss of E-
cadherin in the DTX-resistant cell lines was coupled with upregulation of Vimentin 
(Figure 9D, center panel) and transcription factors Snail and Twist (Figure 9D, center and 
right two panels).  
Vimentin, a well-established marker of EMT [30], was robustly and significantly 
upregulated in the PC3-DR cells compared to sensitive PC3 but its upregulation did not 
reach statistical significance in DU145-DR cells compared to sensitive DU145. Both 
Snail and Twist are known to repress E-cadherin expression, with Twist having a dual 
role in contributing to the upregulation of N-cadherin expression [15, 16, 30]. Taken 
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together, these findings support growing evidence implicating EMT in PCa DTX-
resistance [15, 16, 31].  
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Figure 9. DTX-resistant mCRPC Cells Exhibit a Mesenchymal-like Phenotype 
Compared to DTX-sensitive Cells. (A) Differences in morphology between DTX-
sensitive and DTX-resistant PC3 and DU145 cells visualized by Hoffman modulation 
contrast microscopy (scale bar set at 40 µm). (B) Percent of live PC3 and DU145 cells 
(DTX sensitive and -resistant) that stained positive for E-cadherin and N-cadherin as 
determined by flow cytometry (n=3 biological replicates) *P< 0.05, **P< 0.01, ***P< 
0.001. (C). Representative flow charts of bar graph data showing downregulation of E-
cadherin and upregulation of N-cadherin in the DTX-resistant cell lines. (D) 
Representative Western blots showing expression (upper panels) and quantification 
(lower panels) of E-cadherin (n=3), N-cadherin (n=3), Vimentin (n=3), Snail (n=3), and 
Twist (n=3). *P< 0.05, **P< 0.01,***P< 0.001. Error bars represent mean ± SEM.  
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In addition to these findings, we observed that the DTX-resistant cell populations 
displayed a higher frequency of cells expressing established CSC markers (Figure 10). 
CD44, one of these markers,  is a multifunctional class I transmembrane glycoprotein that 
is highly expressed in most cancer types, where it contributes to tumor progression [32]. 
While we observed a significant proportion of PC3-DR cells with CD44+ expression 
compared to sensitive cells, there was no significant increase in the frequency of CD44+ 
cells in the DU145-DR population (Figure 10A, left two panels). However, because 
CD44 is expressed in almost all normal and cancer cells, specifically in normal prostate 
and PCa cells, there is a reported discrepancy and ambiguity regarding the functional 
aspects of this marker in prostate CSC maintenance [32]. This discrepancy is supported 
by our observation that sensitive DU145 cells showed high CD44+ expression (Figure 
10A, 10B, left panels), and has been circumvented by using CD44 in combination with 
other markers to detect CSC subsets in PCa [32-36].  
To better refine our detection of the putative CSC population in DTX-resistant 
cells, we used the well-validated combination of CD44+/CD24- [32, 35, 36]. CD24 is a 
luminal cell surface protein that contributes to metastasis and functions in cell-cell and 
cell-matrix interactions [32, 33, 36]. Because prostate CSCs arise from the basal cell 
compartment, the CD44+/CD24- marker combination is commonly used to identify these 
cells [32, 33]. We observed that both PC3-DR and DU145-DR cells contained substantial 
CD44+/CD24- subpopulations compared to the sensitive PC3 and DU145 cells (Figure 
10A, 10B, right two panels).  
Elevated aldehyde dehydrogenase (ALDH) activity is also emerging as a 
functional marker of a CSC-like phenotype because of its importance for CSC 
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maintenance, signaling, and drug resistance [37]. To further confirm the acquisition of 
CSC-like characteristics in the DTX-resistant cells, we measured by flow cytometry the 
frequency of Aldefluor+ cells in our DTX-resistance cells compared to sensitive cells. 
Both PC3-DR and DU145-DR showed robust increase of ALDH activity compared to 
their sensitive counterparts (Figure 10C, 10D).  
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Figure 10. DTX-resistant mCRPC Cells Upregulate Markers Associated with CSC-like 
Characteristics Compared to DTX-sensitive Cells. (A) Percent of CD44+ and CD44+/ 
CD24- cells for PC3 vs PC3-DR and DU145 vs DU145-DR, with (B) representative flow 
cytometry plots showing compensation windows used in the FMO analysis for each 
marker. Flow data is represented as frequency of live cells determined by annexin-V 
staining. (C) PC3-DR and (D) DU145-DR cells have a significantly greater percentage of 
ALDH+ cells compared with sensitive PC3 and DU145 cells as determined by aldefluor 
assay (+DEAB control used for gating). Representative flow plots are shown together 
with bar graphs. All flow measurements were acquired from at least 3 independent 
experiments conducted separately. **P< 0.01, ***P< 0.001. Error bars represent mean ± 
SEM. 
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Increased Tumorsphere Formation Capacity and DTX-resistance in DU145-DR Cells 
Upon confirmation of increased frequency of cells expressing EMT and CSC 
markers in the adherent (2D) DTX-resistant cell cultures, we sought to examine and 
compare tumorspheres (3D cultures) formed by sensitive and resistant DU145 cells. 
Tumorsphere formation is a widely used functional approach for enriching CSC 
populations, especially when specific surface CSC markers are not well defined or 
change with tumor heterogeneity [38-40]. We chose to focus these studies on the DU145 
cell line because its DTX-sensitive cells formed large numbers of tumorspheres, 
consistent with previous reports that this cell line has a robust ability to form spheres 
even in the absence of external growth factors or drugs [34]. We observed that under 
tumorsphere-forming conditions, DU145-DR cells showed a 2.3-fold increase in 
tumorspheres compared to sensitive DU145 cells, as evidenced by phase contrast (4X) 
microscopic examination (Figure 11A, 11B). DU145-DR tumorspheres were loosely 
clustered, tethered together in grape-like clusters to form large aggregates (Figure 11C). 
This morphology was a stark difference from the tightly compact tumorspheres of 
sensitive DU145 cells.  
Consistent with our analysis of adherent DTX-resistant cells (2D), flow cytometry 
analysis of DTX-resistant tumorspheres (3D) revealed a decreased frequency of E-
cadherin expressing cells concomitant with increased frequency of N-cadherin expressing 
cells in the DU145-DR 3D cultures compared to DU145 3D cultures, (Figure 11D, 11E, 
left two panels). In addition, we detected increased frequencies of CD44+ and CD44+/ 
CD24- populations in DU145-DR 3D compared to DU145 3D cultures (Figure 11D, 11E, 
right two panels). Furthermore, consistent with the 2D data, DU145-DR tumorspheres 
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had a significantly higher number of Aldefluor+ cells than DU145 tumorspheres (Figure 
11F).  
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Figure 11. Tumorsphere Formation Capacity is Higher in DTX-resistant DU145 Cells 
Compared to Sensitive Cells. (A) Phase contrast microscopy images of DU145 and 
DU145-DR tumorspheres (3D) with (B) quantification of tumorsphere percentage using 
Image J software. (C) Tumorsphere morphology visualized using Hoffman modulation 
contrast microscopy (scale bar set at 40 µm). (D) Percent of live cells positive for the cell 
surface markers E-cadherin and N-cadherin, and CSC markers CD44+/ CD24-, CD44+/ 
CD24-, with (E) representative flow cytometry plots. (F) Representative flow cytometry 
plots showing increased percentage of ALDH+ cells in DU145-DR tumorspheres as 
determined by aldefluor assay with bar graphs. All flow measurements were acquired 
from at least 3 independent experiments conducted separately. *P< 0.05, **P< 0.01, 
***P< 0.001. Error bars represent mean ± SEM.  
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Other groups have demonstrated that tumorspheres derived from DU145 3D cells 
are more resistant to DTX treatment compared to DU145 2D cells [40, 41]. To further 
investigate the link between CSCs and DTX-resistance, we sought to determine if our 
DU145-DR tumorspheres were more resistant to DTX compared to DU145-DR 2D cells 
after exposure to increasing concentrations of DTX for 72 hours. Using propidium iodide 
(PI) staining of dead cells followed by flow cytometric analysis, we found that DU145-
DR 3D tumorspheres were significantly more resistant to 10 nM DTX, the maintenance 
dose of DTX-resistant cell lines compared to the DU145-DR 2D cells grown in 
monolayer (Figure 12A, 12B). There were no statistical differences, however, at other 
lower or higher doses (Figure 12A), or at 24 or 48-hour time points (data not shown).  
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Figure 12. DU145-DR Derived Tumorspheres Show Increased Resistance to DTX 
Compared to DU145-DR Adherent Cells. (A) DU145-DR adherent and tumorsphere 
cells treated with increasing concentrations of DTX (nM range). (B) DU145-DR 3D 
tumorspheres were more resistant to 10 nM DTX than the adherent DU145-DR 2D 
cells. All samples were normalized to untreated controls and to DU145-DR 3D 
percent viability. All measurements were acquired from at least 3 independent 
experiments with 3 biological replicates each. *P< 0.05. Error bars represent mean   
SEM. 
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Discussion 
There is a critical need for new drugs targeting non-traditional molecular targets 
that could be used alone or in combination with current agents for the treatment of 
therapy-resistant mCRPC. The present study used an RNA-seq approach to define 
transcriptomic signatures associated with DTX-resistance with the ultimate goal of 
identifying potentially novel therapeutic targets for overcoming this resistance. For these 
studies, we chose androgen-refractory PC3 and DU145 cells, which are widely used as 
cellular models that emulate late-stage mCRPC disease. While sensitive to DTX-
treatment, these cell lines become resistant to the clinically relevant taxanes DTX, 
cabazitaxel, and paclitaxel upon incremental exposure to DTX and selection of surviving 
cells [8]. Resistance to both DTX and cabazitaxel is inevitable in mCRPC patients 
undergoing chemotherapy [2], but the mechanisms underlying this resistance remain to 
be clearly established.  
PCa is fundamentally AR-driven especially in the context of disease initiation and 
progression. Because the intraprostatic response of PCa cells to androgens depends on the 
expression and sensitivity of AR, ADT has been a mainstay of PCa treatment and 
typically precedes taxane chemotherapy, although data from the recent “STAMPEDE” 
clinical trial showed improved patient survival when long-term primary ADT was 
combined with abiraterone acetate or DTX [42]. Constitutively active AR splice variants 
have been shown to be overexpressed in mCRPC and confer resistance to ADT by 
inhibiting the nuclear translocation of the androgen-AR complex [43-46]. A recent study 
suggested that AR splice variants may also affect sensitivity to taxanes and that tumors 
predominantly expressing the ARv7 variant, associated with ADT resistance, would also 
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be likely be resistant to DTX [47]. However, an independent group was unable to 
replicate these results under similar experimental conditions [48]. Furthermore, another 
group found that detection of ARv7 in circulating tumor cells of mCRPC patients was not 
associated with taxane-resistance and that certain patients with ARv7-positive status at 
baseline converted to ARv7-negative status during the course of taxane therapy, adding 
uncertainty to the clinical significance of this variant in patients receiving taxanes [49]. 
These discrepancies also contributed to our decision to focus on the AR-negative cell 
lines PC3 and DU145 for the present study.  
Our RNA-seq analysis revealed over 1,200 genes that were differentially 
regulated in both the PC3-DR and DU145-DR cell lines. We focused on this set of 
overlap genes because differences in their expression are more likely to reflect 
transcriptomic changes induced by long-term DTX treatment regardless of the PCa cell 
type (e.g., PC3-bone metastasis vs. DU145-brain metastasis). Differentially expressed 
genes within this pool of overlap genes could potentially be exploited as therapeutic 
targets in heterogeneous metastatic prostate tumors that have acquired taxane resistance. 
GSEA of our RNA-seq data revealed several top ranked genes from the overlap dataset 
that an exhaustive PubMed literature review determined as being associated with tumor 
aggressiveness, chemoresistance, or CSC phenotype. Of note, GSEA yielded only one 
significant pathway enriched in the DTX-resistant cell lines compared to sensitive cells 
that yielded 8 genes positive for core enrichment. Of these, 4 genes (ENPP1, CYC1, 
NADHUFAB1, and MYC) are associated with stem cell maintenance, acquisition or 
reprogramming [24-29], suggesting that in PC3 and DU145, DTX-resistance may be 
driven and maintained by the acquisition of CSC-like characteristics. Determining 
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metabolic differences between DTX-sensitive and -resistant mCRPC cells will be 
imperative in future follow-up studies.  
Using qPCR and immunoblotting, we validated several of the top upregulated 
genes in the DTX-resistant cells. These included genes associated with PCa 
aggressiveness, such as FABP5 and BOP1, as well as genes implicated in CSC function 
such as DPP4, TSPAN8, DNAJC12, and NES. FABP5 is an intracellular lipid-binding 
protein that is emerging as a critical regulator of PCa cell proliferation and putative 
marker of aggressive PCa [50-53]. The robust FABP5 transcript and protein upregulation 
observed in the DTX-resistant cells suggest that this protein could be a promising target 
for the treatment of chemoresistant mCRPC. Another gene highly ranked in the GSEA 
was BOP1, an integral component of the ribosomal RNA processing machinery that 
contributes to colorectal tumorigenesis through promotion of cell migration and invasion 
[54, 55]. Interestingly, the BOP1 gene is located in chromosome 8q24, a genomic region 
associated with PCa aggressiveness [54] that also encompasses MYC [56], one of the top 
upregulated genes in the DTX-resistant mCRPC cells revealed by our RNA-seq analysis.  
An emerging stem cell marker, DPP4 (CD26) was also robustly upregulated in the 
DTX-resistant cells. DPP4 is a transmembrane glycoprotein that functions as an 
exopeptidase to promote cell migration through MMP-9, and contributes to the 
upregulation of CD44 [57]. This protein is upregulated in many cancers and associated 
with colon CSCs derived from DTX-resistant cells, which form larger and more 
tumorspheres [58-61]. The robust upregulation in protein expression observed in PC3-DR 
and DU145-DR suggest that DPP4 might be a prostate CSC marker that identifies a 
chemoresistant phenotype. The robust transcript and protein upregulation of TSPAN8 
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(TM4SF3) in the DTX-resistant cells also suggest a role for this protein in PCa 
chemoresistance. TSPAN8, promotes cell-to-cell communication by regulating integrins 
and other cell surface proteins [62], and its expression has been correlated with metastasis 
and worse prognosis in colon cancer where it contributes to cell motility through a 
complex with E-cadherin [63]. TSPAN8 is also considered a pancreatic CSC marker [64]. 
Genome splicing-sensitive microarray analysis revealed upregulation of TSPAN8 and 
DPP4 in DU145 tumorspheres compared to adherent DU145 2D cells [65].  
DNAJC12, also known as Hsp40, has been implicated in cancer but its role in 
tumorigenesis is not clearly defined [66, 67]. The DNAJ family of proteins are 
considered regulators of CSC function [68], and DNAJC12 transcript expression was 
found to be upregulated in breast CSCs compared to adherent breast cancer cells [69]. 
NES, a cytoskeletal intermediate filament protein, has been associated with increased 
migration in PCa cells [70], and increased NES expression correlated with high tumor 
grade, invasive phenotype, and predictor of poor response to therapy [71]. Consistent 
with our observation that NES is robustly upregulated in DTX-resistant mCRPC cells 
with CSC-like characteristics, NES expression was previously reported in PCa 
tumorspheres that showed increased chemoresistance to paclitaxel [72], and was 
associated with a mesenchymal phenotype [73].  
Oncomine data analysis comparing transcript expression of DPP4, TSPAN8, and 
NES between prostate tumor tissues and normal tissues revealed inconsistent 
upregulation of these genes in the different datasets. An explanation for this could be that 
the prostate tumors used to generate most of these gene expression datasets were not 
derived from advanced or chemoresistant disease. Alternatively, gene expression changes 
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found in DTX-resistant cells occur in only a small subset of cells, most likely those with 
stemness properties. Since tumors contain varying proportions of cells with and without 
stemness properties, it will be difficult to consistently detect global gene expression 
changes in CSCs present in PCa tissues since they comprise a minority of the population. 
A limitation of the Oncomine database is the assessment of gene expression in normal vs. 
PCa tissues without extensive clinical data (type of treatment, tumor stage, etc.) for 
several of the datasets. Therefore, to further validate the expression of selected genes of 
interest in clinically relevant tissues, it will be important in future studies to obtain 
mCRPC biospecimens with annotated clinical data from patients with and without taxane 
treatment, and that responded to or failed the treatment. We recognize, however, the 
intrinsic difficulties in obtaining such biospecimens.  
The beneficial effects of chemotherapeutic drugs like DTX are hindered by the 
development of chemoresistance. Emerging evidence demonstrates that a small 
population of CSCs present within the tumors possesses multiple redundant mechanisms 
that facilitate tumor cell survival in the presence of therapeutic agents [12, 14, 17]. In 
addition, the relatively non-proliferative state of CSCs makes this small population of 
cells intrinsically resistant to conventional chemotherapies, most of which target rapidly 
dividing cells. This resistant population comprises a tumor cell reserve that persists even 
after anti-proliferative treatments and repopulates the tumor in metastatic sites [12]. The 
emerging role of CSCs in the acquisition of PCa chemoresistance [12, 15, 17, 74], and 
the observation that highly-ranked genes in our RNA-seq analysis were associated with a 
CSC-like phenotype or genetic program, led us to characterize this population in DTX-
sensitive and -resistant mCRPC PC3 and DU145 cells. Putative CSCs are typically 
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identified based on the presence and/or absence of several cell surface markers, the 
combination of which is specific for the CSC-like phenotype identified in a particular 
tumor type [71]. Our observation that the PC3-DR and DU145-DR cell cultures were 
enriched with cell populations expressing several of these CSC markers, including 
significantly elevated ALDH activity compared to DTX-sensitive parental cells, is 
consistent with the acquisition of CSC-like characteristics. Furthermore, our finding that 
DU145-DR cells have an enhanced capacity to form tumorspheres (3D) and increased 
ALDH activity compared to DU145 tumorspheres, is an indicator of the increased CSC-
like characteristics of the resistance cells. In addition, our DU145-DR tumorspheres 
showed increased resistance to 10 nM DTX, a clinically relevant dose, compared to 
adherent DU145-DR cells (2D), suggesting that a CSC-like phenotype contributes to 
enhanced DTX resistance. An accurate assessment of the increased tumorigenic potential 
of DTX-resistant cells with CSC-like characteristics would be more effectively achieved 
through in vivo studies with animal models using enriched CSC populations acquired by 
cell sorting.  
Targeting CSCs is a promising approach to circumvent tumor chemoresistance 
[14, 17]. Current strategies focus on targeting signaling pathways upregulated in stem 
cells that are specific to their function, including the Hedgehog, Wnt, Notch, and NFkB 
pathways [12]. The present RNA-seq study provides additional candidate genes and 
molecular pathways for potential therapeutic targeting, and contributes to the emerging 
body of evidence linking CSCs to PCa chemoresistance. Future pre-clinical studies will 
focus on establishing mechanistic roles of specific genes identified in our RNA-seq 
analysis in the maintenance of prostate CSCs and driving taxane resistance, validating 
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their expression in clinical biospecimens derived from PCa patients that failed taxane 
therapy, and investigating their potential as therapeutic targets. It will also be important 
to further define PCa cell-type dependent differences in the expression of CSC and 
chemoresistance-associated genes, as our RNA-seq analysis demonstrated that PC3-DR 
and DU145-DR cells have differentially regulated genes that are unique to each of these 
cell lines. This would be critical for tackling the high heterogeneity that characterizes 
prostate tumors. 
 
Materials and Methods 
Cell Lines, Antibodies, and Cell Culture 
The metastatic PCa cell lines PC3 and DU145 were purchased from the American 
Type Culture Collection (ATCC, Cat# ATCC-CRL-1435 and ATCC-HTB-81, 
respectively). Cells were cultured as recommended by the supplier in RPMI medium 
(Thermo Fisher Scientific) supplemented with 10% fetal bovine serum, 
penicillin/streptomycin, and gentamicin. Cells were maintained in a humidified incubator 
with 5% CO2 at 37°C. DTX-resistant (DR) PC3 and DU145 were developed as described 
previously [18]. Briefly, PC3 and DU145 cells were cultured in media containing 1 nM 
DTX (LC Laboratories Cat# D-1000) and surviving cells were passaged four times before 
increasing the concentration of DTX. This was repeated until resistant cells could be 
maintained with minimal cell death in the presence of 11 nM DTX.  
Short tandem repeat (STR) profiling is a recommended and validated method for 
authentication of human cell lines and tissues [75]. The importance of cell line 
authentication is highlighted by the NIH initiative for rigor and reproducibility in 
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scientific research [76], and is particularly important for scientific studies such as the 
present one that use established cancer cell lines for pre-clinical mechanistic studies. We 
utilized the STR service provided by ATCC (Cat# ATCC 135-XV) to authenticate the 
PC3 and DU145 cell lines used in this study. Both cell lines matched their respective 
database profiles. The DTX-resistant PC3-DR and DU145-DR cell lines were derived 
from these validated PC3 and DU145 parental cell lines. 
 
RNA Isolation and RNA-seq Library Preparation and Sequencing 
Total RNA was extracted from DTX-sensitive and -resistant PC3 and DU145 cells using 
the miRNeasy Mini Kit (Qiagen Cat# 217004). RNA-seq library construction and 
sequencing was performed at the Loma Linda University School of Medicine Center for 
Genomics. RNA-seq library was constructed using the TruSeq Stranded mRNA Low 
Sample Preparation protocol (Illumina; Cat# RS-1229004DOC). Two µg of total RNA 
were used as input. Each RNA sample was spiked with 1:100 ERCC RNA spike-in 
control mix 1 (Life Technologies, Cat# 4456740) prior to the first step of the protocol. 
All the recommended controls were used during subsequent steps including an End 
Repair Control, A-Tailing Control, and Ligation Control. The RNA-seq libraries were 
quantified using Qubit 3.0, and the quality of RNA-seq libraries was checked on Agilent 
TapeStation. All RNA-seq libraries were sequenced on Illumina HiSeq 4000 at the Loma 
Linda University Center for Genomics, with 150 bpx2, Paired-End. Quality control was 
confirmed (Figure 13 and 14).  
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Figure 13. Quality Assessment Metrics for RNA-seq Data. Box plots representing 
interquartile range and median of (A) GC content (%) and (B) the Phred quality score 
distribution over all reads across all 12 samples in each base. 
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Figure 14. Quality Assessment on External RNA Spike-in Controls. (A) Percentage of 
reads mapped to genomic regions including exon, intron, and intergenic region. (B) Plot 
of log2(FPKM) of ERCCs detected from samples spiked with ERCC Mix1 vs log2 (spike-
in concentrations). 
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RNA-seq Data Analysis 
For mRNA-seq data visualization and analysis, we utilized pipelines that 
integrated the QC (FastQC, ShortRead), trimming process (trimmomatic), alignment 
(Tophat2), reads quantification (cufflinks), and differentially expressed gene (DEG) 
analysis (cuffdiff) as described previously [77]. Briefly, the RNA-seq raw fastq data were 
first trimmed using Trimmomatic (V0.35). The trimmed reads were aligned to the human 
reference genome (NCBI GRCh38) with TopHat V2.1.1 with default parameter settings. 
The aligned bam files were then processed using Cufflinks V2.2.1 for gene 
quantification. Reads were then mapped to ERCC transcripts and quantified using 
TopHat V2.1.1 and Cufflinks V2.1.1 with default parameter settings. Genes with FPKM 
≥ 1 in all samples were used for DEG analysis. Differentially expressed genes (DEGs) 
were identified by Cuffdiff with FDR > 0.05, and fold change (FC) > 2.  
  Hierarchical clustering heat map and PCA of global genes for all cell lines were 
performed with “R” program (http://cran.r-project.org/) [78] and Partek Genomics Suite 
6.6, respectively. GSEA (v3.0, Broad Institute) [79, 80], was performed to compare 
parental DTX-sensitive PC3 and DU145 with DTX-resistant DU145-DR and PC3-DR. 
Gene sets were obtained from published gene signatures in the Molecular Signatures 
Database v1.0 (MSigDB). Analysis was run with 1,000 permutations and a classic 
statistic. Normalized enrichment score and p-values were measured to find enrichments 
with statistical significance (p<0.05). 
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Quantitative Reverse Transcription PCR (RT-qPCR) 
For confirmation of RNA-seq results, we selected specific genes for independent 
in-house validation of their differential regulation in DTX-sensitive vs. -resistant cell 
lines. Briefly, total RNA was extracted from cell lines using the RNAprotect reagent 
(Qiagen Cat# 76526) and the RNeasy plus mini kit (Qiagen Cat# 74134). RNA (0.5 µg) 
was reverse transcribed into cDNA using iScript cDNA synthesis kit (Bio-Rad Cat# 
1708891). Primer sequences for gene validation were commercially synthesized by 
Integrative DNA Technologies (IDT) (see Table 4). Quantitative polymerase chain 
reaction (qPCR) was performed on the MyiQ real-time PCR and CFX96 Touch Real-
Time PCR (Bio-Rad) detection system using iQSYBR Green Supermix (Bio-Rad Cat# 
170-8882) according to the manufacturer’s instructions. The cycling conditions were 
95°C for 15 min, 95°C for 15s, 60°C for 60s for 35 cycles, followed by melt analysis 
from 60 to 95°C. Expression levels were normalized to the housekeeping gene 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Samples were analyzed in at least 
four independent biological replicates performed experimentally in triplicates. 
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Table 4. Primer Sequences for qPCR 
Gene! Forward!Sequence!(5’!to!3’)! Reverse!Sequence!(5’!to!3’)!
'
DPP4'
'
CTCCAGAAGACAACCTTGACCATT
ACAGAA'
'
TCATCATCATCTTGACAGTGCAGT
TTTGAG'
'
TSPAN
8'
'
TTGCTTCTGATCCTGCTCCT'
'
TTTTTCACTTTCCCCTGTGG'
'
NES'
'
CTCCAAGAATGGAGGCTGTAGGAA'
'
CCTATGAGATGGAGCAGGCAAGA'
'
DNAJC
12'
'
CAGACAAGCATCCTGAAAACCC'
'
TCGCCAGTGGTCATAGCGGGC'
'
FABP5'
'
ACCCTGGGAGAGAAGTTTGAAGA'
'
TGTAAAGTTGCAGACAGTCTGAGT
TTT'
'
BOP1'
'
CCATGCCGAGTCTTACAACCCACC'
'
AGCAGCAACACGGCATCATCCAT
GGC'
'
ABCC3'
'
CTGTGCACACAGAAAACCCG'
'
GGACACCCAGGACCATCTTG'
'
TGM2'
'
TAAGAGATGCTGTGGAGGAG'
'
CGAGCCCTGGTAGATAAA'
'
GAPDH'
'
CGAGATCCCTCCAAAATCAA'
'
TTCACACCCATGACGAACAT'
!
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Immunoblotting Procedures 
Whole cell lysates were prepared and the protein concentration in the lysates was 
determined using the BioRad DC Protein Assay Kit (Cat# 5000112) to ensure equal 
loading of proteins per lane. Bands were separated by SDS-PAGE (NuPAGE 4-12%, 
Thermo-Fisher Scientific) followed by transfer to polyvinyl difluoride membrane 
(Millipore). Membranes were blocked with either 5% dry milk solution or 5% bovine 
serum albumin both prepared in TBS-T buffer (20 mM Tris-HCL, pH 7.6, 140 mM NaCl, 
0.2% Tween 20) and probed with the following primary antibodies: Rabbit anti-
LEDGF/p75 (1:1000, Bethyl Laboratories Cat# A300-848A), mouse anti-clusterin alpha 
chain (1:1000, Millipore Cat# 05-354), rabbit anti-MDR1/ABCB1 (1:1000 Cell Signaling 
Cat# 13342), rabbit anti-DPP4/CD26 (1:3000, Millipore Cat# MABF752), mouse anti-
Nestin (1:1000 Millipore Cat# MAB5326), rabbit anti-DNAJC12 (1:500, Novus Cat#  
NBP1-57718), rabbit anti-FABP5 (1:5000; a kind gift from Marino De Leon, Loma 
Linda University, Loma Linda, CA), mouse anti-Snail (1:1000, Cell Signaling Cat# 
3895S), mouse anti-Twist (1:200,  Santa Cruz Cat# sc-81417), rat anti-Vimentin (1:8000, 
R&D Systems Cat# MAB2105-SP), rabbit anti-TGM2 (1:1000, Cell Signaling Cat# 
3557), rabbit anti-BOP1 (1:1000, Bethyl Cat# A302-148A-M-1), mouse anti-E-cadherin 
(1:500, BD Biosciences Cat# 610182), or mouse anti-N-cadherin (1:200, Abcam Cat# 
ab12221). The mouse anti-TSPAN8 primary antibody was from Celine Greco and Claude 
Boucheix (1:2000) [81].  
Following several washes with TBS-T, membranes were incubated with the 
appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies (anti-mouse 
IgG and anti-rabbit IgG, Cell Signaling Cat# 7076 and 7074, respectively; goat anti rat, 
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Santa Cruz Cat# sc-2032). HRP-!-actin was utilized as a loading control (Cell Signaling 
Cat# 5125). After 2-hour incubation with secondary antibodies, the membranes were 
washed several times with TBS-T, and protein bands were detected by enhanced 
chemiluminescence (Thermo Fisher Scientific, Cat# 34580). Bands were quantified using 
Image J software (National Institutes of Health) and normalized to !-actin control. 
Samples were analyzed in at least 3 independent experiments using at least 3 biological 
replicates.  
 
Bioinformatics Analysis of Oncomine Cancer Gene Microarray Database 
For analysis of mRNA expression of genes of interest in PCa and normal prostate tissues, 
we selected 16 datasets from the Oncomine database (Compendia Biosciences; Ann 
Arbor, MI; www.oncomine.org). These datasets, derived from gene microarray analyses 
of PCa and normal prostate tissues, provide fold-change data for gene expression with P 
values calculated by Oncomine using Student’s t-tests. The Grasso dataset included 35 
castration-resistant metastatic PCa, 59 localized PCa, and 28 benign prostate tissue 
specimens while the Varambally dataset included 6 hormone-refractory metastatic PCa 
samples in addition to 7 localized PCa, and 6 normal prostate samples. This allowed us to 
compare the transcript expression between these 3 categories of tissues in our genes of 
interest. 
 
Tumorsphere Forming Assays 
Cells were cultured in 6-well non-tissue culture treated plates at a density of 
25,000 cells/ml, and suspended in F12K/RPMI supplemented with 1% knockout serum 
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replacement (Fisher Scientific Cat# 10828028), 20 ng/ml human EGF (Millipore Sigma 
Cat# E9644), 10 ng/ml human bFGF (PeproTech Cat# 100-18B), 0.1% of albumin 
solution 35% in PBS (Sigma Cat# 091M8416), 1% Pen-Strep, 0.1% insulin (Millipore 
Sigma Cat# 10516), and 0.1% selenium (Millipore Sigma Cat# 229865). After 24 hours 
the floating cells were collected and cultured in separate plates in the medium described 
above. Cells were left for 14 days adding or replacing medium as necessary to maintain 
growth. Images of cells were taken after at least 14 days post-plating using an Olympus 
IX70 microscope with phase contrast and Hoffman modulation contrast and equipped 
with a SPOT RT3 imaging system. Using phase contrast 4X images and Image J 
software, tumorsphere formation was quantified as percent area in at least four 
independent experiments.  
 
Flow Cytometric Analysis of Stem Cell Markers, ALDH Activity, and Cell Death 
Adherent PC3-DR and DU145-DR cells were cultured in monolayer to 80-90% 
confluency prior to collection for multicolor flow cytometric analysis of putative CSC 
markers. Cells were washed with PBS and harvested using a solution containing 0.25% 
Trypsin and 2.21mM EDTA (Corning Cat# 25-053-Cl), followed by incubation in fresh 
fully supplemented RPMI medium containing 10% FBS for 30 minutes to allow for N-
Cadherin and E-Cadherin recycling following enzymatic cleavage. In parallel, 
tumorspheres derived from PC3-DR or DU145-DR cells were collected and dissociated 
using 0.25% Trypsin/2.21mM EDTA solution, followed by neutralization with fresh 
fully-supplemented medium. Following the 30-minute recovery period, cells were then 
labeled with antibodies against CD44, CD24, N-Cadherin, E-Cadherin, or annexin-V for 
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15 minutes at room temperature (see Table 5 for antibody specifications). Cells were 
washed and resuspended in annexin-V binding buffer (50 mM HEPES, 700 mM NaCl, 
12.5 mM CaCl2; pH 7.4) and analyzed immediately on a MACSQuant Analyzer 10 
equipped with violet, blue, and red lasers (Miltenyi Biotec). Post-acquisition data analysis 
was performed using FlowJo version 10.08.1 (BD).  
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Table 5. Antibodies Used for Detection of EMT and CSC Markers by Flow Cytometry. 
Antibody Fluorochrome Manufacturer Information Laser 
CD44 V450 
BD Biosciences 
Cat# 561292 
Clone: G44-26 
Violet 
Annexin-V FITC Life Technologies Cat# V13242 
Blue 
CD24 PE BD Biosciences Cat# 555428 
N-Cadherin PE-Vio770 
BD Biosciences  
Cat# 56345 
Clone: 8C11 
E-Cadherin PE-Vio770 Miltenyi Biotec Cat# 130-099-142 
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 ALDH activity was detected using Aldefluor assay kit purchased from Stem Cell 
Technologies (Cat# 01700) and performed according to manufacturer’s instructions. 
Briefly, 2D and 3D cells were prepared and harvested as described above. 400,000 cells 
were resuspended in 200 µl of aldefluor buffer and 2 µl of aldefluor reagent to form the 
“test” sample (both provided). 200 µl of that text mix were then immediately transferred 
to another microcentrifuge tube containing 2 µl of DEAB reagent (provided) to inactivate 
the aldefluor reagent and become the “control” sample. Both the control and test sample 
were incubated for 45 minutes at 37°C. Samples were then centrifuged and resuspended 
in aldefluor buffer to be analyzed immediately on the MACSQuant Analyzer. Post-
acquisition data analysis was performed using FlowJo version 10.08.1 (BD) with gates 
being drawn on the control DEAB+ samples for each cell line 2D and 3D.  
Initial gates for intact cells using FSC-A/SSC-A light scatter and doublet 
discrimination using FSC-H/FSC-A profiles. Single-stained samples were used to define 
compensation matrices. Following compensation, dead cells were excluded based on 
annexin-V positivity and only live cells were assessed for putative CSC marker 
expression. Gate placements were defined using Fluorescence-Minus-One (FMO) 
controls using SSC-A versus marker of interest (Figure 15 for gating strategy and Table 5 
for staining strategy for FMO detection). Data are presented as percent of live cells 
staining positive for each designated marker and are representative of at least 3 
independent experiments. 
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Debris Exclusion Doublet Discrimination
CD24 Gate
Live Cell Gate
CD44 GateN-Cadherin GateE-Cadherin Gate
 
Figure 15. Gating Strategy for Multicolor Flow Cytometric Analysis of CSC Markers in 
Cells Grown in Adherent (2D) or Non-adherent (3D) Conditions. Following 
compensation, gates were set for SSC-A versus marker expression based on 
Fluorescence-Minus-One (FMO) controls (inset). 
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Table 6. Fluorescence-Minus-One (FMO) Staining Strategy for Detection of CSC 
and EMT Markers by flow cytometry 
Antibody CD44 Annexin-V CD24 N-Cadherin E-Cadherin 
Unstained Control - - - - - 
CD44 Only + - - - - 
Annexin-V Only - + - - - 
CD24 Only - - + - - 
N-Cadherin Only - - - + - 
E-Cadherin Only - - - - + 
FMO-CD44 - + + + + 
FMO-AV + - + + + 
FMO-CD24 + + - + + 
FMO-N-Cadherin + + + - + 
FMO-E-Cadherin + + + + - 
Full Stain + + + + + 
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Detection of Cell Viability by Propidium Iodide Staining 
PC3 and DU145 cells, DTX-sensitive or -resistant, were seeded in 6-well cluster 
plates at 1.25x105 cells per well and allowed to adhere for 24 hours. Separately, PC3-DR 
and DU145-DR cells were seeded in non-adherent conditions in 6-well cluster plates at 5 
x104 cells per well. Cells were then treated with increasing concentrations of DTX (0.1, 
1, 10, 100, 1000 nM) for 72 hours, followed by PI staining using the Dead Cell Apoptosis 
Kit for flow cytometry (Life Technologies, Cat# V13242) according to the 
manufacturer’s instructions. Briefly, adherent cells were detached from culture using 
0.25% Trypsin/2.21mM EDTA solution for 30 seconds, followed by neutralization using 
complete RPMI medium containing 10% FBS. Cells grown in non-adherent conditions 
were collected from culture medium and dissociated using 0.25% Trypsin/2.21mM 
EDTA solution for 30 seconds, followed by neutralization using complete medium 
containing 10% FBS. Cells were washed with PBS, suspended in annexin-V binding 
buffer and stained with PI (1µg/ mL final concentration) for 15 minutes at room 
temperature in the dark, then immediately analyzed on a MACSQuant Analyzer. 
Following exclusion of debris and doublet events, single-stained samples were used to 
define compensation matrices and experimental gates. Data are presented as percentage 
of cells staining negative for PI (percent viability) (see Figure 16 for gating strategy).  
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Figure 16. Gating Strategy for Flow Cytometric Analysis of Cell Death. Propidium 
iodide (PI) staining was analyzed in DU145 and DU145-DR cells grown in adherent or 
non-adherent conditions following 72 hours of exposure to DTX. Gates for PI were set 
using unstained controls on pooled samples (right inset).  
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Statistical Analysis 
Statistical analysis and graph generation was performed using GraphPad Prism 
version 6.0c for Mac OSX (GraphPad Software, La Jolla, California USA, 
www.graphpad.com). Fold change differences in both qPCR, immunoblotting, Oncomine 
data, and tumorsphere percent area were analyzed using Student’s t-test. Results were 
considered significant at P < 0.05. One-Way ANOVA was used for the analysis of results 
from PI staining experiments comparing percent viability in the resistant 2D (adherent) 
compared to resistant 3D (tumorspheres) cultures.  
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CHAPTER THREE 
SELECTED UNPUBLISHED DATA 
 
LEDGF/p75 May Play a Role in Regulating Inflammatory Cytokines Contributing 
to PCa Aggressiveness and Chemoresistance 
 Lens Epithelial Derived Growth Factor  (LEDGF/p75) is an emerging stress 
oncoprotein implicated in the transcriptional regulation of survival proteins, contributing 
to cancer aggressiveness and chemoresistance [1-6]. Work done in our lab demonstrated 
that LEDGF/p75 is upregulated in clinical prostate tumors and contributes to taxane-
resistance in PCa cells [7-9]. Furthermore, targeting of this protein with RNA 
interference partially resensitizes DTX-resistant cells to docetaxel [10]. The role of 
inflammation in PCa initiation and progression has long been established [11], with 
inflammatory cytokines such as IL-6 and IL6-R being implicated in PCa aggressiveness, 
chemoresistance, and increased serum levels of IL6 in PCa being associated with poor 
prognosis [11-14].  In addition, overexpression of LEDGF/p75 has been shown to induce 
IL-6 in human keratinocytes. We hypothesize that LEDGF/p75 plays a role in regulating 
inflammatory cytokines thereby contributing to PCa aggressiveness and chemoresistance.  
To identify inflammatory cytokines regulated by LEDGF/p75 in PCa cells, we 
monitored changes in inflammatory gene expression using quantitative real time PCR 
pathway specific gene arrays, focusing on the RT2 Profiler Human PCR Inflammatory 
Response and Autoimmunity Array (QIAGEN). Transcient knockdown was done on PC3 
cells, PC3-DR and DU145-DR cells. RNA was extracted 48-hours post siRNA 
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transfection. RNA was purified, cDNA was made and used to run the inflammatory 
arrays comparing each knockdown to the appropriate scrambled control.  
LEDGF/p75 knockdown in DTX sensitive PC3 cells was associated with 
downregulation of IL-6 and IL-6R transcripts (Figure 17A& B). Consistent with this, 
Western blotting analysis showed increased cellular levels of IL-6 and IL-6R in response 
to LEDGF/p75 overexpression. These studies were repeated using both DTX-sensitive 
and resistant DU145 PCa cells. Our RT-PCR results also indicate that in the context of 
chemoresistance, depletion of LEDGF/p75 may play a role in the downregulation of 
inflammatory genes such as CCL5, CXCL2, IL-6, NF-kB, TIRAP, and TLR4 (Figure 
17B). The most robust gene downregulation in response to LEDGF/p75 depletion in 
chemoresistant PCa cells was that of IL-6 (Figure 17B).  
To further validate these preliminary results, it was important to use in-house 
primers for the determined genes of interest and immunoblotting to demonstrate 
upregulation in DTX-resistant cells and downregulation with knockdown of LEDGF/p75. 
Preliminary RT-qPCR data demonstrated upregulation of IL-6 in PCR-DR and DU145-
DR cells (which overexpress endogenous LEDGF/p75) compared to parental PC3 and 
DU145 cells (Figure 18A& B). In addition, immunoblotting revealed increased 
expression of IL-6R in DTX-resistant and LEDGF/p75-overexpressing PC3 cells, and 
increased protein expression of IL-6 in DU145-DR cells (Figure 18C). While the 
upregulation of IL-6 protein in the PC3-DR and DU145-DR cells was consistent with the 
RT-PCR array results from LEDGF/p75-depleted cells, the IL-6R upregulation observed 
in these DTX-resistant cells was in stark contrast with that observed in LEDGF/p75-
depleted cells (Fig. 17B). Furthermore, we were not able to show by immunoblotting the 
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downregulation of IL-6 protein in cells depleted of LEDGF/p75 (data not shown), 
suggesting that either LEDGF/p75 does not regulate directly this inflammatory cytokine, 
or the IL-6 protein levels in the DR cells are very stable and not totally dependent on 
transcript levels.  
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Figure 17. Inflammatory Gene Arrays Reveal Possible Target Genes of LEDGF/p75. A. 
siRNA-mediated knockdown of LEDGF/p75 in a panel of PCa cell lines. B. RT2 Profiler 
RT-PCR inflammatory gene array results showing common candidate gene up- or down- 
regulated in DTX- sensitive and resistant PCa cell lines in response to LEDGF/p75 
knockdown. C. The model suggests that when PCa cells transition from chemosensitive 
to chemoresistant the stress protein LEDGF/p75 is upregulated and may contribute to the 
upregulation of specific inflammatory genes. *Significant (p<0.05) Upregulation in Red 
and Downregulation in Blue. 
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Figure 18. Preliminary Validation of Inflammatory Array Results. A. RT-PCR data 
showing upregulation of IL-6 in the PC3-DR and DU145-DR PCa cell lines compared to 
the parental PC3 and DU145 cells. B. RT-PCR data showing upregulation of IL-6R in the 
DTX-resistant PC3 and DU145 PCa cell lines compared to the parental PC3 and DU145 
cells. C. Western blot data showing that increased expression of IL-6 and IL-6R protein 
correlates with increased LEDGF/p75 expression in PC3-DR, DU145-DR, and 
LEDGF/p75 overexpression PCa cell lines compared to parental PCa cells.  
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Further development of these preliminary studies will help elucidate mechanisms 
by which LEDGF/p75-induced stress and inflammatory genes contribute to 
chemotherapy resistance in PCa (Figure 17). The potential role of LEDGF/p75 in co-
regulating inflammatory cytokines also has important implications for understanding the 
role of LEDGF/p75 in healthy individuals and autoimmune disease. This is critical given 
recent observations that LEDGF/p75 is the target of autoantibodies in subsets of healthy 
individuals and patients with miscellaneous inflammatory or autoimmune conditions 
[15].  
 
Migratory Potential of DTX-resistant Cells Compared to DTX-sensitive Cells 
The ability for cancer cells to migrate and invade surrounding tissue is an 
indicator of their aggressiveness. Using techniques such as migration assays we are able 
to determine the effects of a drug or targeting of a gene on a cell line’s migratory 
potential. There is inconsistency in the literature on the effects of DTX-resistance on cell 
migration. Although DTX-resistant cells are more aggressive and have a mesenchymal-
like phenotype we observed in scratch/wound assays reduced migration in DTX-resistant 
PC3-DR and DU145-DR cells compared to DTX-sensitive PC3 and DU145 cells (Figure 
19). As shown in Chapter 2, when PC3 and DU145 cells become resistant to DTX they 
upregulate markers of EMT and CSC-like phenotype. As such, they migrate differently as 
individual cells, a phenomenon termed single-cell migration, which causes cells to detach 
individually and reattach at the center of the scratch/wound, versus migrating as a group 
of cells to close the wound [16].  
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Figure 19. Representative Scratch-wound Images with Graphs Showing Percent Wound 
Recovery. Results show that the DTX-resistant PCa cells (A, PC3-DR and B, DU145-
DR) have less percent wound recovery compared to the DTX-sensitive cells (A, PC3 and 
B, DU145). Results were statistically significant (p<0.0001).  
  
A
B
!
0
20
40
60
80
***
PC3$$$$$$$$$$$$$PC3DR
%
$W
ou
nd
$R
ec
ov
er
y
!
!
0
20
40
60
80
***
!!!!DU145!!!!!!!!DU145DR
%
!W
ou
nd
!R
ec
ov
er
y
!
!
PC3$DR
DU145$DR
!
0
20
40
60
80
***
PC3$$$$$$$$$$$$$PC3DR
%
$W
ou
nd
$R
ec
ov
er
y
!
!
0
20
40
60
80
***
!!!!DU145!!!!!!!!DU145DR
%
!W
ou
nd
!R
ec
ov
er
y
!
!
0$HR 24$HR
0$HR 24$HR
0$HR 24$HR
0$HR 24$HR
PC3$
DU145$
  
108 
Co-targeting LEDGF/p75 and CLU Individually and Together in Combination with 
DTX to Resensitize DTX-resistant PCa Cells to Taxane Therapy 
 Current trends in cancer treatment emphasize combinatorial therapies targeting 
multiple redundant, but distinct, cell signaling pathways to more effectively sensitize 
cells to standard therapies [17]. Clusterin (CLU) is an anti-apoptotic protein that protects 
cells from stressors such as chemotherapy and androgen deprivation. It is upregulated in 
several cancers and is well defined as a key contributor to PCa resistance to taxane drugs   
[18-21]. Like LEDGF/p75, CLU is highly upregulated in the mCRPC cell lines PC3 and 
DU145 after progressive treatment with DTX, leading to induction of chemoresistance 
[18, 19, 21]. Downregulation of CLU also results in sensitization to DTX cytotoxicity in 
these chemoresistant cells [18]. Thus, LEDGF/p75 and CLU appear to play similar, if not 
redundant, roles in promoting taxane resistance in PCa.  
 Both LEDGF/p75 and CLU are stress survival proteins that are overexpressed in 
DTX-resistant PC3 and DU145 cell lines, and promote taxane resistance. Therefore, we 
first determined if their expression was interdependent. Western blot analysis showed that 
in PC3 cells with stable LEDGF/p75 overexpression, CLU was not overexpressed, 
compared to vector control, suggesting that overexpression of CLU in these cells may be 
independent of LEDGF/p75 overexpression (Figure 20A). In addition, siRNA-mediated 
knockdown of LEDGF/p75 in PC3 cells with ectopic overexpression of LEDGF/p75, and 
in DTX-sensitive and –resistant PC3 and DU145 cells did not result in downregulation of 
CLU expression (Figure 20B), again supporting the view that CLU expression is 
independent of LEDGF/p75 expression.  
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Figure 20. Knockdown Studies Reveal that CLU and LEDGF/p75 Expression are 
Independent. Both proteins are upregulated in DTX resistant (DR) cells (A) Knockdown 
of LEDGF/p75 in DTX-sensitive or resistant cells does not result in downregulation of 
CLU (B), whereas knockdown of CLU does not result in consistent downregulation of 
LEDGF/p75 (C). 
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Western blot analysis of protein lysates from DTX-sensitive and DTX-resistant 
PC3 and DU145 cell lines with CLU knockdown showed a slight downregulation of 
LEDGF/p75, which was not consistent in all cell lines (Figure 20C). This can be 
explained by the fact that CLU knockdown by itself causes apoptotic cell death, leading 
to caspase-mediated LEDGF/p75 degradation [22], which could explain the slight 
downregulation of this protein observed in Figure 20C.  
Given that LEDGF/p75 and CLU exhibit redundant roles in promoting DTX 
resistance, through two distinct mechanisms (inhibition of caspase-independent cell death 
vs caspase-dependent cell death, respectively) [5, 18, 19], we sought to co-target these 
proteins to more effectively re-sensitize chemoresistant PCa cells to taxane therapy. We 
performed single or double siRNA-mediated knockdowns of CLU and LEDGF/p75 in the 
DTX-resistant PC3-DR and DU145-DR for 48 hours in the presence of 10 nM DTX 
(maintenance dose of DTX) and analyzed the morphology of the cells via Hofmann 
Modulation Contrast microscopy. As expected, double knockdown of LEDGF/p75 and 
CLU resulted in greater cell death than single knockdown of each protein (Figure 21). To 
quantify levels of cell death, cell viability was determined by MTT assay up to 96 hours 
(Figure 22A& B), and by Annexin/PI staining using flow cytometry (Figure 23A& B). 
Using both assays to assess cell viability after single and double knockdown of CLU and 
LEDGF/p75 in the presence of DTX, our results showed no difference in cell viability 
between the double knockdown and CLU knockdown, suggesting that the effects 
observed in the double knockdown are due largely to the effects of silencing CLU.  
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Figure 21. SiRNA-mediated Double Knockdown of LEDGF/p75 and CLU is More 
Effective in Resensitizing PC3-DR PCa cells to DTX Than Knocking Down Each Protein 
Alone. (A) Knockdown was verified by immunoblotting. (B) Double knockdown shows 
increased cell death compared to single knockdown of CLU or LEDGF/p75. 
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Figure 22. MTT Assay Reveals Double Knockdown of LEDGF/p75 and CLU Does Not 
Result in More Cell Death than CLU Knockdown Alone. MTT assay was done 48, 72, 
and 96 hours post knockdown. Experiment was repeated three times in triplicates with no 
significance found between si-CLU knockdown and siLEDGF/p75-siCLU double 
knockdown 
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Figure 23. Flow Cytometry Reveals No Significant Increase in Cell Death in the Double 
LEDGF/p75 and CLU Knockdown Compared to Clusterin knockdown alone. AV/PI 
staining was done 72 hours post knockdown in the presence of 10 nM DTX. L3 refers to 
the si-LEDGF/p75 knockdown. This experiment was repeated two times.  
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Targeting LEDGF/p75 with SMIs to Resensitize Chemoresistant mCRPC Cells to 
DTX Treatment 
  In addition to its role in cancer, LEDGF/p75 also facilitates HIV-1 integration 
into transcriptionally active sites in host chromatin by interacting with the HIV-integrase 
(HIV-IN) [23]. Novel small molecule inhibitors (SMIs) targeting the HIV-IN binding 
domain (IBD) of LEDGF/p75, located within its C-terminus, have been developed [24] 
(Figure 24) .  
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Figure 24. Model of LEDGF/p75 Structure Illustrating the IBD Domain. The IBD 
domain, a site crucial in transcriptional and stress survival activity and the predicted site 
of SMI binding. 
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developed pharmacophore models mimicking LEDGF/p75 IBD res-
idues K364, I365, and D366. The structure of a lead N-acylhydraz-
one that was identified from the pharmacophore models and
inhibited LEDGF/p75-IN interaction in vitro with an IC50 value be-
low 25 lM is provided in Figure 1. The pharmacophoric mapping of
similar LEDGF/p75-IN inhibitors prompted an investigation into
the importance of the central N-acylhydrazone linker. Several lead
molecules containing N-acylhydrazones were then subjected to
substructure and similarity studies which led to the discovery of
new acylhydrazone and hydrazine-based LEDGF/p75-IN inhibitors.
N-Acylhydrazones are known to treat tuberculosis via a mech-
anism of action targeting the biosynthesis of mycolic acids of the
bacteria cell wall.25,26 Antibacterial salinizide, aconiazide, and
other acylhydrazone prodrugs are hydrolyzed to the active hydra-
zide component isoniazid (Fig. 2).27,28 N-acylhydrazones have also
been identified to have antiretroviral activity by binding to HIV-1
capsid29 and reverse transcriptase30,31 suggesting potential antivi-
ral activity for this class of LEDGF/p75-IN inhibitors. In this study
we identified acylhydrazones, hydrazines, and diazenes as
LEDGF/p75-IN inhibitors, examined their SAR, and explored strate-
gies to evade cellular metabolism.
2. Results and discussion
2.1. SAR for the inhibition of HIV-1 IN and LEDGF/p75
interaction
2.1.1. Acylhydrazones
Developing small molecule inhibitors that target allosteric
pockets and alternate stages of the viral life cycle is the next step
in a marathon against expanding pools of drug-resistant strains.
We identified N-acylhydrazones as a potential new lead compound
using LEDGF/p75 IBD-based pharmacophore models. The examina-
tion of small molecules with a central acylhydrazone evolved from
a series of SAR studies using substructure searches. Further LEDGF/
p75-IN inhibitors were identified from a commercial database (En-
amine, Ltd) of half a million compounds and screened using an
amplified luminescent proximity homogeneous assay.32
Structures of select N-acylhydrazones and related compounds
are shown in Figure 3. Compounds 4 and 5 both inhibited
LEDGF/p75-IN interaction with an IC50 value of 4 lM (Table 1).
Changing the position of the pyridine nitrogen from a meta (5) to
an ortho position in compound 6 improved activity three-fold with
an IC50 of 1.3 ± 0.3 lM. A pyrazine-carbohydrazine (7) exhibited
the best activity with an IC50 of 0.4 ± 0.1 lM while compound 8
had a pyrazine opposite a dichlorobenzylidene and was inactive
at 50 lM. Unlike LEDGF/p75-IN inhibitors 4–7, compounds 3 and
8 lacked a phenol ring and did not exhibit inhibitory activity at
50 lM.
LEDGF/p75-IN inhibitors containing a pyrazole followed a sim-
ilar pattern of activity. Compounds 10–12 without a phenol ring
were inactive at 50 lM while 13 had an IC50 of 2 ± 1 lM, at least
a 25-fold improvement. Compounds 9 and 15 both had 2-hydro-
xyl-naphthalene moieties and similar inhibition profiles. Com-
pound 16 had a pyrazole instead of a bicyclic ring and also
yielded similar activity with an IC50 of 7 ± 3 lM.
The presence of a phenol in compounds 1–16 seems to have im-
proved LEDGF/p75-IN inhibition. Other examples of hydroxyben-
zylidene acylhydrazones will need to be tested to confirm this
conclusion. Prodrug strategies have previously been explored to
evade the cellular metabolism associated with acylhydrazones.33
In our assays, the anti-tuberculosis drug, isoniazid, did not inhibit
the LEDGF/p75-IN interaction at 1000 lM (data not shown). Inter-
estingly, 4,6-bis(ethylamino)-1,3,5-triazine-2-carbohydrazide (19)
had an IC50 value of 6 ± 2. Substituting the terminal hydrazide with
a carboxamide linker (20) reduced activity more than threefold.
Replacing the pyrazole of 16with a thiofuran (21) did not maintain
inhibitory activity, while compound 22 with a hydroxythiophene
showed a weak potency. Compounds 26 and 27 had an IC50 of
8 ± 3 and 13 ± 5 lM, respectively.
It is plausible that the hydroxyl group in some of the 2-phenol-
based inhibitors are important for LEDGF/p75-IN inhibitory activ-
ity. Many of the inactive analogues replace the hydroxyl group
with a methoxyl group or a chlorine while most of the isoniazid-
like compounds (e.g., 17 and 18) tested also do not have a 2-phe-
nol. As docking studies reveal in Section 2.2, it is likely the hydro-
xyl group in the 2 position forms an important hydrogen bond with
the target IN dimer interface, thus disrupting the LEDGF/p75-IN
complex.
LEDGF/p75-IN inhibitors were also tested against HIV-1 IN cat-
alytic activities in vitro (Table 1). Compound 7 did not inhibit IN at
100 lMwhile the LEDGF/p75-IN inhibitor 6 exhibited dual activity
with a catalytic inhibitory profile for 30 processing and strand
transfer IC50 values of 17 ± 5 and 13 ± 3 lM, respectively. The
remaining LEDGF/p75-IN inhibitors containing pyridines or pyra-
zines were all inactive at 100 lM against IN catalytic activities
in vitro. The bromine-substituted compound 14was the only other
acylhydrazone to inhibit strand transfer with an IC50 value of
15 lM. HIV-1 IN catalytic inhibition by LEDGF/p75-IN inhibitors
has been previously identified to induce multimer formation and
lock IN into an inactive state.17
It has also been suggested that many of the reported dual 2-
(quinolin-3-yl) acetic acid LEDGF/p75-IN inhibitors act to prevent
IN assembly on the viral DNA prior to the integration step.34 Since
NI HYD HBD HBD
Figure 1. A lead molecule with an N-acylhydrazone was identified from a four
feature pharmacophore model mimicking LEDGF/p75 IBD K364, I365, and D366
residues key to viral replication. Representative hydrogen bond donor (HBD) groups
in purple, a hydrophobic (HYD) group in teal, and a negative ionizable group in a
dashed blue circle is shown. New compounds were explored focusing on a central
N-acylhydrazone and two opposite cyclic rings, all components not highlighted as
pharmacophore model-related groups.
Figure 2. Clinical acylhydrazone-containing drugs have widely been used for tuberculosis.
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These SMIs disrupt the LEDGF/p75-HIV-IN interaction, likely by binding to this 
C-terminal IBD, which is essential for HIV integration [23]. The transcriptional and 
stress survival functions of LEDGF/p75 also depend on the structural and functional 
integrity of its C-terminus [1, 22]. Therefore, we hypothesized that repositioning these 
HIV-based SMIs is a promising strategy to overcome mCRPC chemoresistance. SMIs 
were obtained from Enamine LLC designed by Sanchez, et al [24] DTX-resistant PC3 
and DU145 cells were seeded in 96 well plates with and without DTX. 24 hours later 
different concentrations (0.1, 1, 10, 100 and 100 nM) of each SMI #14 (Cat# T5756746), 
46 (Cat # T5863733), 71(Cat# T5251403), 91(Cat# T5755298), and 118 (Cat# 
T05189618) from Enamine LLC (Figure 25A) with and without DTX were added to each 
well in triplicates. After 72 hours MTT assay was performed. Preliminary data suggested 
that select candidate LEDGF/p75 SMIs #14, 46, 71, and 91 promote selective 
chemoresistance to 10 nM DTX in DTX-resistant PC3-DR and DU145-DR cells (Figure 
26B& C). Concentration of 10 nM for each SMI is shown because that is where the 
change is first noticed and subsequent concentrations were similar (data not shown). 
Future studies will require determining the cytotoxic activity of these selected SMIs in 
the presence of various concentrations of DTX, establishing that these SMIs bind to 
LEDGF/p75, and that they disrupt LEDGF/p75 interactions with other proteins and 
transcriptional activity.  
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Figure 25. Top SMIs (# 14, 46, 71, 91, 118) that have Cytotoxic Activity in DTX-
resistant PCa Cells Alone (gray bars) or in Combination with DTX. A. Chemical 
structure of inhibitors were designed by Sanchez, et al., 2013. B& C. % Viability 
determined using MTT assay. Experiment shown is done with 10 nM SMI concentration 
and 10 nM DTX treatment is shown above. Experiment done two times. Gray bars 
represent SMI inhibitor treatment only, green or orange designates SMI treatment with 
DTX.  
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Adherent and Tumorsphere PC3-DR and DU145-DR Cells Upregulate CSC 
Markers CD133+ and CD117+ 
To better define the CSC population in the DTX-resistant cell lines, we performed 
flow cytometric analysis using the marker combinations of CD44+/CD24- [25-27], and 
CD44+/CD24-/CD133+ or CD44+/CD24-/CD117+ [26, 27]. CD133 expression is 
associated with tumor progression, self-renewal capacity, and metastasis colonization and 
growth [26]. CD117, also known as c-kit is associated with tumor progression, 
metastasis, and resistance to therapy [26]. We observed that PC3-DR cells showed a 
statistically significant increase of CD44+/ CD24-/ CD133+ cells. DU145-DR cells also 
showed an increase of this subset, although not significant. Both PC3-DR and DU145-
DR displayed a significant increase of CD44+/ CD24-/ CD117+ cell subpopulations 
compared to the parental, drug-sensitive PC3 and DU145 cells (Figure 26).  
In addition, we detected increased frequencies of CD44+, CD44+/ CD24- and 
CD44+/ CD24-/ CD133+ populations in DU145-DR 3D compared to DU145 3D 
tumorspheres (Figure 27A). Although we also observed an increase in the CD44+/CD24-
/CD117+ population in DU145-DR 3D tumorspheres, this finding did not reach statistical 
significance (Figure 27B).  
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Figure 26. DTX-resistant mCRPC Cells Upregulate Markers of CSC-like Phenotype 
Compared to DTX-sensitive Cells, as Measured by Flow Cytometry. (A) CD44+/ CD24, 
CD44+/ CD24-, CD44+/ CD24-/ CD133+, and (B) CD44+/ CD24-/ CD117+. All flow 
measurements were acquired from at least 3 independent experiments, *P<0.05, 
**P<0.01. Error bars represent mean ± SD. 
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Figure 27. DU145 and DU145-DR Tumorsphere Cells Upregulate Markers of CSC-like 
Phenotype Compared to DTX-sensitive Cells, as Measured by Flow Cytometry. (A) 
CD44+/ CD24-, CD44+/ CD24-, CD44+/ CD24-/ CD133+, and (B) CD44+/ CD24-/ 
CD117+. All flow measurements were acquired from at least 3 independent experiments, 
*P<0.05, **P<0.01. Error bars represent mean ± SD. 
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CHAPTER FOUR 
OVERALL DISCUSSION 
Despite recent advances in the treatment of advanced PCa including Sipuleucel-T, 
abiraterone acetate, enzalutamide and CTX [1, 2], resistance to therapy occurs, resulting 
in patient death within three years of diagnosis [3-6]. DTX is the current gold standard 
for chemotherapeutic treatment of castration resistant tumors. Unfortunately, most 
patients receiving DTX experience taxane chemoresistance and disease progression 
within seven months of starting treatment [1, 2, 7]. Newer therapeutic agents such as 
CTX (also a taxane derivative) have demonstrated some overall survival benefit of 
slightly over a year [8]. Therefore, there is an unmet need for new therapeutic drugs used 
alone or in combination with current chemotherapeutic agents for the treatment of 
mCRPC. The goal of this study was to utilize RNA-seq to define molecular signatures 
associated with DTX-resistance in metastatic PCa cells in order to identify novel 
therapeutic targets for overcoming this resistance.  
Examining the RNA-seq data, we observed that of the 33,118 total genes 
examined, 3,754 genes in the DU145-DR cell line had a significant fold change 
difference compared to the parental DTX-sensitive DU145 cell line, and 2,552 genes in 
the PC3-DR cell line had a significant fold change difference compared to the PC3 cell 
line. We chose to focus our studies on the 1,254 genes that were shared or overlapped 
between both PC3-DR and DU145-DR cells because these particular differences in gene 
expression are common to both DTX- resistant cell lines and likely result from long-term 
DTX treatment. GSEA analysis of the RNA-seq data revealed top ranked genes from the 
overlap data set, with many of these genes been associated with tumor aggressiveness, 
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chemoresistance, or a CSC-like phenotype. We selected some of the top upregulated 
genes in the DTX-resistant cells, including DPP4, TSPAN8, DNAJC12, and NES for 
validation using qPCR and immunoblotting. In addition, we validated FABP5 and BOP1, 
genes associated with PCa aggressiveness.  
FABP5 is an intracellular lipid-binding protein that is emerging as a critical 
regulator of PCa cell proliferation [9, 10], and targeting FABP5 decreased malignant 
progression of CRPC cells in vivo [11]. Recent studies also suggest that FABP5 is a 
possible marker for aggressive PCa with FABP5 expression associated with high Gleason 
score [12]. Oncomine analysis demonstrates an upregulation of FABP5 expression in 
prostate tumors vs. normal, providing further evidence for the role of FABP5 in PCa. 
Considering the contribution of FABP5 to an aggressive phenotype in combination with 
our results demonstrating a robust transcript and protein fold upregulation in both PC3-
DR and DU145-DR cells, FABP5 may be a promising target for the treatment of 
chemoresistant mCRPC.  
BOP1 is an integral component of the ribosomal RNA processing machinery and 
a vital component of colorectal tumorigenesis through the promotion of cell migration 
and invasion. BOP1’s role in cell migration was demonstrated by the observation that its 
loss contributed to a regression of EMT and an increase in E-cadherin expression, 
suggesting it may be an upstream inducer of EMT [13, 14]. With our observation of 
increased EMT phenotype in the DTX-resistant cell lines, these results suggests that 
BOP1 may play a similar role in PCa by contributing to upregulation of EMT in PC3-DR 
and DU145-DR cells. In addition, the Oncomine analysis revealed an upregulation of 
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BOP1 transcript expression in prostate tumor vs. normal, and BOP1 transcript and protein 
expression was upregulated in DTX-resistant cell lines.   
DPP4, also known as CD26, is a transmembrane glycoprotein that functions as an 
exopeptidase that can inactivate incretins, chemokines, and promotes cell migration 
through the upregulation of MMP-9 [15]. DPP4 is upregulated in many cancers including 
lung, T-cell lymphomas, thyroid, and prostate [16, 17], and plays a role in a CSC 
phenotype in colon cancer [18-20]. In addition, DPP4 contributes to upregulation of 
CD44, another CSC marker [15]. Furthermore, CD26+ colon CSCs derived from DTX-
resistant colon cancer cells were found to form larger and more abundant colonospheres 
[18]. Consistent with the RNA-seq data, DPP4 transcript and protein fold expression was 
upregulated in the PC3-DR and DU145-DR cells compared to the sensitive PC3 and 
DU145 cells. This suggests that DPP4 may be a possible prostate CSC marker that 
identifies a chemoresistant phenotype.  
TSPAN8, also known as Co-029 and TM4SF3, is a member of the tetraspanin 
family consisting of membrane proteins important in direct and indirect communication 
between cells by regulating integrins and other cell surface proteins [21]. Also robustly 
upregulated in the RNA-seq analysis (sensitive vs. resistant), this protein is positively 
correlated with metastasis and worse prognosis in esophageal [22], liver [23], and colon 
cancers, where it has been shown to be involved in cell adhesion and motility through a 
complex formed with E-cadherin [24]. In addition, TSPAN8 is considered a CSC marker 
in pancreatic cancer [25], and whole genome splicing-sensitive microarray analysis in 
PCa cells revealed an upregulation of DPP4 and TSPAN8 in DU145 CSC tumorsphere 
(3D) population compared to adherent DU145 cells (2D)  [26]. This provides evidence 
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for the potential role of TSPAN8 and DPP4 upregulation contributing to a CSC 
phenotype. As with DPP4, TSPAN8 transcript and protein fold expression was 
upregulated in the resistant PC3-DR and DU145-DR cells.  
DNAJC12, also known as Hsp40, is a member of the heat shock protein family 
and acts as a co-chaperone that can modulate the function of protein complexes. Little is 
known about the role of this protein in cancer but it may contribute to tumorigenesis [27, 
28]. Oncomine data revealed consistent upregulation of DNAJC12 in PCa versus normal 
tissue. We report a possible role of DNAJC12 in PCa chemoresistance by demonstrating 
a transcript and protein upregulation of this protein. In addition, the DNAJ family of 
proteins have a suggested role as key regulators of CSC function, making them an 
attractive target for drug design [29].  DNAJC12 transcript expression has been shown 
upregulated in breast cancer stem cells compared to normal cells [30].  
NES is a cytoskeletal intermediate filament protein that was first identified as a 
marker of neuroepithelial stem/progenitor cells in the brain and is associated with 
increasing migration in PCa cells and their expression is induced by androgen deprivation 
[31]. In many tumor types, increased NES expression is correlated with high tumor grade 
and is suggested to be an indicator of an invasive phenotype in breast, ovarian, 
gastrointestinal tumors, and melanoma, where NES is also a predictive marker of poor 
response to therapy [32]. NES was also found in PCa cells and tumospheres expressing 
stem cell markers including Nanog, Oct4, Sox-2, and CD133, and these tumorspheres 
were found to be more chemoresistant [33]. Similar to our studies, NES was also found to 
be increased in hepatocellular carcinoma drug resistant cell lines, and was associated with 
a mesenchymal phenotype [34]. In breast cancer, NES was found to promote 
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proliferation, survival, and migration of breast CSCs by enhancing the Wnt/β-catenin 
activation, a mechanism that may be at play in other cancer types [35].  
Chemotherapeutics, like DTX, have temporary cytotoxic effects on the bulk 
tumor, due to the small population of CSCs with multiple redundant mechanisms that 
facilitate cell survival. In addition, the non-proliferative state of CSCs make them cellular 
reserves that allows for a small population of cells to persist even after anti-proliferative 
treatments and repopulate the tumor or metastasize [36]. With the identification of the 
emerging role of CSCs in the acquisition of PCa chemoresistance [6, 36-38], and with the 
observation that many highly-ranked genes were associated with a CSC phenotype or 
programming, we chose to characterize this population in DTX-resistant PC3-DR and 
DU145-DR cells and DTX-sensitive PC3 and DU145 cells to determine if CSC 
frequency was increased in the DTX-resistant cells.  
CSCs are typically identified based on the presence and/or absence of several cell 
surface markers, the combination of which is specific for the CSC-like phenotype 
identified in a particular tumor type [32]. The observation that the PC3-DR and DU145-
DR (2D) adherent cells upregulate CSC markers is consistent with the CSC hypothesis, 
where therapy resistance develops in part to a small population of cells that are inherently 
resistant and remain dormant during therapy treatment. When the majority of the bulk 
tumor is eradicated, this CSC-like population remains and is able to repopulate the area 
with cells that are resistant to treatment and upregulate proteins important in pathways 
maintaining and promoting metastasis [36]. In addition, the mesenchymal phenotype 
displayed by these resistant cells drives this CSC-like phenotype contributing to 
aggressive disease progression.  
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The link between EMT and CSC is largely unexplored, but recent evidence 
suggests that upregulation of EMT proteins and pathways results in a CSC-like 
phenotype including self-renewal and therapy resistance [39]. We report here that PC3-
DR and DU145-DR cells have a higher frequency of cells expressing CSC-like markers, 
and higher ALDH+ activity. In addition, the DU145-DR 3D cells formed larger and more 
abundant tumorspheres compared to the DTX-sensitive DU145 3D cells, and these 
tumorspheres were more resistant to DTX showing increased viability with 10 nM DTX 
treatment. 
 DTX is currently the gold standard treatment for mCRPC and its use ultimately 
results in therapy resistance. This important work reveals genes that are upregulated upon 
DTX treatment and acquisition of resistance, and that most likely contribute to the 
resistance phenotype. Therefore, targeting the pathways involving these genes, including 
those responsible for CSC development, in combination with DTX is a promising 
strategy to circumventing chemoresistance.   
 
Conclusions and Future Directions 
Current targeting of CSCs focuses on the signaling pathways upregulated in stem 
cells that are specific to their function. These pathways include Hh, Wnt, Notch, and 
NFkB pathways [36], and targeting them has not resulted in any treatments for 
chemoresistant patients.  This study contributes to the growing body of evidence linking 
CSCs to PCa chemoresistance [40, 41] and provides a set of genes for possible targeting 
that are implicated in contributing to this CSC phenotype. Many of the other genes highly 
ranked by GSEA analysis have roles in cancer and PCa as well as undefined functions, 
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suggesting that although CSCs or CSC-associated genes are promising targets for new 
treatments, there are many other pathways and mechanisms that are still largely 
undefined in this data set, including the role of FABP5 and BOP1 in chemoresistance. It 
will also be important to explore the cell type-dependent differences in PC3 and DU145 
cells that exist between the resistant phenotypes of these cell lines, evident by the genes 
not overlapped or shared between them.  
RNA-seq studies provide the framework for research aimed at elucidating new 
mechanisms and pathways associated with a DTX-resistant phenotype in order to 
discover novel targets for future PCa treatments. Future studies will involve targeting the 
top-ranked genes to determine their function in CSC acquisition or DTX-resistance. 
Targeting can be done using siRNAs, pharmacological inhibitors, SMIs or antibodies as 
is the case with TSPAN8 [42]. Promising candidates will have readily available inhibitors 
or validated antibodies that are used in other cancer types. The goal is to show that 
inhibition of this protein or pathway associated with the expression of these proteins, will 
lead to a disruption in tumorsphere formation, or resensitization of DTX-resistant cells. In 
vivo models will be crucial to determining the effect inhibition of these proteins on tumor 
volume, metastasis, and/or chemoresistance.  Furthermore, future studies should also 
focus on validating our RNA-seq data in CSCs derived from PCa patients that developed 
taxane resistance.  This will help us identify and prioritize more precisely candidate genes 
for therapeutic targeting. 
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CHAPTER FIVE 
METHODOLOGY 
The contents described in this chapter are for the purpose of instructing current 
and future laboratory members on the key methodologies utilized in this project. This 
section will provide key details and nuisances that are crucial to reproduce the 
experiments presented in this dissertation. Furthermore, these methods may assist in 
troubleshooting common setbacks that may occur when repeating these techniques for 
follow-up studies.  
 
Cell Culture 
The PC3 and DU145 cell lines used in this study were purchased from ATCC; 
please refer to the “ATCC Culture Methods” section on their website for specific 
protocols and required growing conditions. These cell lines were also authenticated 
through ATCC’s STR profiling service. This authentication step should be done before 
any major publication when using a cell line that was purchased a long time ago (no 
record remains) or came from another lab. Two additional cell lines were used, PC3-DR 
and DU145-DR, which were derived from PC3 and DU145 and passaged in the presence 
of docetaxel (DTX) chemotherapy to be drug resistant (DR). The protocol for generation 
these DTX-resistant cell lines is in the dissertation of Leslimar Ríos-Colón entitled 
“Targeting LEDGF/p75 to Sensitive Chemoresistant Prostate Cancer Cells to Taxanes” in 
the “Methodology” chapter. For this study, PC3, PC3-DR, DU145, and DU145-DR cells 
were thawed from frozen stocks obtained from the liquid nitrogen storage tank. Each 
frozen vial was prepared in freezing medium (Fetal Bovine Serum [FBS] supplemented 
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with 10% DMSO) and stored in a box labeled “Du Ross” in the large liquid nitrogen 
storage tank. T25 flasks filled with 5 mL of RPMI-1640 cell culture medium were pre-
warmed in the incubator for at least 10 minutes prior to adding the cells. RPMI-1640 (500 
mL) medium consisted of 10% FBS, 100!µl of gentamycin and 1 ml of normocin to 
prevent bacterial and fungal contamination. Frozen vials were thawed in the 37°C water 
bath (without submerging to prevent contamination), added immediately to pre-warmed 
T25 flask with 5 mL of medium, and placed in the incubator. Incubation conditions were 
95% air, 5% carbon dioxide, at 37oC. Cells typically attach within 24 hours, at which 
point the medium should be changed to remove the DMSO present in the freezing 
medium.  
Once cells were confluent, which could take between 24-72 hours depending on 
the cell density at the time of culture passaging (often referred to as splitting), they were 
expanded to a T75 flask. When cells are not confluent enough to passage (80-100%), 
medium should be changed every 48-72 hours. Be careful not to split cells at anything 
less than 60-70% confluent, since this will result in slower proliferation over time. Also 
be careful not to ignore cells for more than 72 hours, since this will result in stress 
pathways being upregulated due to serum starvation caused by over confluency and may 
alter the “normal” behavior of your cell line. If cells are left too long without splitting, 
they may start undergoing cell death so do not use them for experiments and thaw out a 
new vial, otherwise you may not get consistent results.  
 The PC3-DR and DU145-DR cells require the addition of 10 nM DTX to the 
medium each time the medium is changed, either during splitting or routine medium 
change. 10 mM DTX stocks are kept in the -20°C freezer and one stock is typically kept 
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in the freezer located in the cell culture room. Dilution steps are as follows: add 1 µl of 
10 mM DTX to 99 µl of RMPI complete medium to make a 100 µM stock and label “A”;  
then take 10 µl of A and add to 90 µl of RMPI medium to make a 10 µM stock and label 
“B”; finally take 50 µl of B and add to 950 µl of RMPI to make a 500 nM stock and label 
“C” . Add 200 µl of C to a T75 flask with 10 mL RPMI media to get the final10 nM DTX 
concentration required. Following these dilution steps will lead to more consistent DTX 
concentrations versus adding 1 µl of DTX to 1000 µl of RMPI and adding 10 µl of this to 
the T75 flask.  
 
Mycoplasma Testing 
 It is crucial to test cell lines for mycoplasma contamination once thawed or at 
least every 6 months and use normocin antibiotics in the medium to prevent 
contamination. Some lab members do not use normocin in their medium, so their cells 
should be quarantined and kept in a separate incubator away from other cells in the lab. 
This is important to ensure that mycoplasma contamination does not occur, which is very 
difficult to eliminate. Any contaminated cell lines that cannot be easily acquired again 
will need to be treated with normocin for at least 6-8 months to rid of contamination. For 
this reason, normocin should be added to the media used for every cell line grown in the 
lab. Exceptions should be reviewed by the PI so that appropriate risk assessment can be 
made. In addition, cell lines that were not grown in normocin should not be frozen and 
used by the general lab, only by the individual working with them. If they are thawed for 
distribution to lab members, they need to be tested immediately and grown in medium 
containing normocin for maintenance and prevention of contamination. There is currently 
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no evidence that normocin usage will alter cell function or disrupt any selection process, 
with the exception of protocols that call for antibiotic-free media. Mycoplasma testing is 
done using the MycoAlert PLUS Mycoplasma Detection Kit from Lonza (Cat# LT07-
701) following manufacturers’ instructions. Normocin is purchased from Invivogen (Cat# 
ant-nr-1). 
 
Preparation of Whole Cell Lysates 
 To collect cells from flasks, medium was aspirated and the walls of the flask were 
rinsed with 2-4 mL of sterile PBS. The PBS was aspirated and 1 mL trypsin was added to 
the flask, which was placed in the incubator for a few minutes. Note that some cell lines, 
especially the parental PC3 and DU145 require more time in trypsin than the DTX-
resistant cells, which detach from the flask relatively easily. If cells do not appear to be 
detaching, a gentle tap from the outside may be enough to detach the cells. Be careful not 
to leave trypsin on for too long or tap the flask too vigorously, some cell lines, DU145 in 
particular, are sensitive to vigorous tapping and may grow slowly or in clumps as a result.  
Cells were collected in 10 ml plastic tissue culture tubes and stored short-term on 
ice. Cells were then spun for 4 minutes at 6,000 RPM (centrifuging speed may vary 
depending on cell line) in a centrifuge, and the supernatant was discarded. Pellets were 
transferred to a 1 ml microcentrifuge tube and washed two times with PBS to remove any 
residual trypsin and media. This step is crucial to removing albumin, a highly abundant 
protein in cell culture media that may interfere with sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting procedures. The 
cell pellet was dissolved in Laemmli sample buffer containing a protease inhibitor 
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cocktail (LSB:CPI). The amount of buffer added depended on the size of the pellet. It is 
important not to add too much buffer, which could dilute the protein concentration and 
make it difficult to load enough protein for immunoblotting. Conversely, adding too little 
LSB:CPI may result in adding very small volumes of the sample to wells in the gels,  
which may decrease loading consistency. This is because pipetting any volume under 1 
µl reduces accuracy. Typically, 150-200 µl of LSB-CPI was added for a pellet derived 
from one confluent T75 flask and 30-100 µl for a pellet derived from one confluent well 
in a 6-well plate. Lysates may be stored in -80°C at this point, or they may be sonicated 
immediately. The lysates were sonicated to ensure proper disruption of cell membranes 
and chromatin and passed multiple times through a Hamilton syringe. The lysate was 
boiled in the 100°C heat block for 10 minutes. Lysates are stored permanently in the -
80°C.  
 
Antibodies 
 The commercial antibodies used in this study were as follows: Rabbit anti-
LEDGF/p75 (1:1000, Bethyl Laboratories Cat# A300-848A), mouse anti-Clusterin alpha 
chain (1:1000, Millipore Cat# 05-354), rabbit anti-MDR1/ABCB1 (1:1000 Cell Signaling 
Cat# 13342), rabbit anti-DPP4/CD26 (1:3000, Millipore Cat# MABF752), mouse anti-
Nestin (1:1000 Millipore Cat# MAB5326), rabbit anti-DNAJC12 (1:500, Novus Cat#  
NBP1-57718), rabbit anti-FABP5 (1:5000; a kind gift from Marino De Leon, Loma 
Linda University, Loma Linda, CA), mouse anti-Snail (1:1000, Cell Signaling Cat# 
3895S), mouse anti-Twist (1:200,  Santa Cruz Cat# sc-81417), rat anti-Vimentin (1:8000, 
R&D Systems Cat# MAB2105-SP), rabbit anti-TGM2 (1:1000, Cell Signaling Cat# 
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3557), rabbit anti-BOP1 (1:1000, Bethyl Cat# A302-148A-M-1), mouse anti-E-cadherin 
(1:500, BD Biosciences Cat# 610182), or mouse anti-N-cadherin (1:200, Abcam Cat# 
ab12221). The mouse anti-TSPAN8 primary antibody was a kind gift from Celine Greco 
and Claude Boucheix (1:2000).  
 
Immunoblotting Procedures 
Immunoblotting was performed as follows: equal amounts of protein from whole cell 
lysates were loaded into individual wells of 4-12% polyacrylamide gradient gels (SDS-
PAGE, NuPAGE, Thermo Fisher Scientific). Protein concentrations were determined 
utilizing the DC protein assay kit from BioRad following the manufacturers’ instructions. 
To compare changes in protein expression, especially slight changes, only 5-10 µg should 
be loaded onto wells to avoid saturating the chemiluminescence signal. Typically, 15-20 
µg is ideal for most antibodies, but titer or sensitivity of each antibody should be 
considered. Proteins were separated by SDS-PAGE and transferred onto polyvinyl 
difluoride membranes (PVDF) (Millipore) in a NuPAGE electrophoresis system from 
Thermo Fisher Scientific.  
 Protein sample preparation included 5 µl of NuPAGE LDS sample buffer (4X), 2 
µl of NuPAGE reducing agent (10X), and cell lysate. Water was added to make a final 
loading volume of 20 µl. Protein separation was done in MOPS-SDS running buffer for 
60 minutes at 175 volts. Protein transfer to PVDF membranes was done in diluted 1X 
Transfer Buffer (20X Transfer Buffer purchased from Invitrogen) with 100 µl of 
antioxidant added. To confirm complete protein transfer, membranes were rocked slowly 
at room temperature in Ponceau S stain for 10-20 minutes depending on the protein 
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concentration loaded. The membrane was washed gently in double distilled water until 
the amount of protein loaded in each well was clearly visible. Images were captured by 
cell phone camera, printed, and documented in the lab notebook. Membranes were then 
blocked in 5% milk prepared in TBS-T buffer (20 mM Tris-HCL, pH 7.6, 140 mM NaCl, 
0.2% Tween 20) for 1-2 hours. Some antibodies required blocking with 5% BSA 
prepared in TBS-T. Blocking with either milk or BSA was done at room temperature on 
the rocker. All membranes used in these studies were then probed with primary antibody 
overnight in the cold room rocker. Not all primary antibodies require overnight 
incubation since some antibodies can be exposed to membranes for 2-4 hrs with excellent 
results. Thus, each new primary antibody must be optimized for milk vs BSA blocking 
buffer, overnight vs 2-4 hr incubation with membranes, appropriate dilution, and cell 
line-dependent target protein expression.  
If multiple antibodies were used on the same membrane they would either be 
added on different days after developing the first one, or the membrane was cut based on 
molecular weight regions and each strip individually probed with the corresponding 
antibody targeting a protein migrating in a specific region. Alternatively one can probe 
the membrane simultaneously with two same species antibodies [rabbit, human, mouse] 
recognizing proteins in distant regions of the membrane (e.g 75 kD and 25 kD proteins) 
to prevent non-specific interactions or interference caused by mixing different species 
antibodies. This however, has never worked well in my experience for the antibodied 
used in these studies and resulted in “smeared” and “fuzzy” bands. It is important to note 
that the amount of Tween-20 added to the 1X TBS may vary depending on the procedure. 
We used 0.2% Tween-20 for every experiment in this study, but other preferred 
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concentrations include 0.1-0.15% Tween-20 depending on the antibody. Using too much 
Tween-20 may wash away the antibody from the membrane or prevent tight antibody 
binding to target protein; using too little, however, may require extensive washing to get 
a clean, background-free membrane, which could also result in lower protein signal 
detection. For new antibodies, this may also need to be optimized.  
Antibody dilution is different depending on the specific antibody and the 
expression levels of its target protein in different cell lines or tissue types. When using a 
new antibody, it is important to optimize the immunoblotting protocol to determine the 
appropriate dilution and protein concentration for each cell line. Following the 
manufacturer suggestions typically may not work but these can be used as a starting point 
to determine a dilution range for optimizing. When optimizing new antibodies, more 
concentrated dilutions (ranging 1:100-1:500) should be tested against increasing protein 
concentrations (5-30 ug) to determine optimal concentration. Antibodies should also be 
optimized for reactivity in 5% milk or BSA, unless either of these is specifically 
recommended in the manufacturer’s product specification sheet..  
 The membrane with primary antibody was washed three times with TBS-T on the 
rocker at room temperature, changing TBS-T every 10 minutes. After this, secondary 
HRP-conjugated antibody was added for 1-2 hours depending on the primary antibody 
and amount of protein loaded. Membranes were washed as before and enhanced 
chemiluminescence (ECL) was used to detect immunoreactivity. ECL was added to 
membranes in a wet chamber for 4 minutes, after which the membranes were transferred 
to autoradiography cassettes and exposed to autoradiography film for different time 
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period to get a range of exposure times that provide an accurate representation of the 
immunoreactivity.  
Images were quantified using ImageJ software and statistical analysis of protein 
fold change, relative to beta-actin or tubulin loading controls, was done using PRSIM 
software. It is important to get overexposed and underexposed blots in addition to 
moderate exposure because this allows for an accurate interpretation of the strength of the 
immunoreactivity. In addition, getting the optimal exposure for both the protein band of 
interest and the actin or tubulin becomes crucial when bands are quantified using ImageJ. 
Bands that are too overexposed are difficult to quantify accurately since they are out of 
the linear signal range (i.e. the chemoluminescent signal is saturated). We used exposure 
times that allowed for clear visualization of spaces between adjacent bands in a gel and 
that showed undersaturated bands.  
 
RNA Extraction for RNA-sequencing  
 It is important to ensure that RNA samples to be used for RNAseq studies are of 
the highest quality. When working with RNA, it is crucial to clean with ethanol and 
RNase Eliminator the workbench and any other surface or object that will come in 
contact with the RNA including pipettes, chemical bottles, centrifuge handles, etc. Apply 
the RNase eliminator directly to a clean paper towel after using ethanol. Do not add it 
directly to a surface or object, it is very dense and forms suds that take a long time to dry. 
Total RNA was extracted from prostate cancer cells using the miRNeasy Plus Mini Kit 
(Qiagen, Cat# 217004) per manufacturers’ protocol for “Purification of Total RNA from 
Animal Cells” found in the miRNeasy Mini Handbook (Qiagen website: 
 144 
https://www.qiagen.com/us/resources/resourcedetail?id=632801fb-abc5-4e62-b954-
ff51f126a34f&lang=en). Chloroform and 100% ethanol are not provided in the kit and 
must be purchased separately. Do not use the 190 proof ethanol used for cell culture, it is 
important to obtain 100% ethanol and be mindful that if the bottle is opened frequently, it 
may not retain the purity necessary for this protocol. Briefly, the protocol encompasses 
sample preparation that involved lysing of the cellular membranes, binding of RNA to the 
silica filter, washing of contaminants, and elution of pure RNA.  
 “Step 1b” and “Step 2” from the protocol were utilized for disruption of cells 
grown on monolayer. For Step 7, the centrifuge in the cold room was utilized for the 15-
minute centrifugation and separation. In addition, all optional steps in the protocol to 
increase yield were followed (Steps 11 and 14). For Step 16, to increase RNA yield, 30 µl 
of RNase-free water was used to elude the RNA into the collection tube twice. This 
provided for maximum efficiency of the elution filter. Collected RNA was immediately 
put on ice in a clearly labeled tube and given to the LLU Genomics core for storage in 
their -80 freezer prior to RNA sequencing.  
 
RNA Extraction for Quantitative Real-Time PCR 
 As with RNA extraction for RNAseq samples, the workspace must be cleaned 
thoroughly with ethanol and RNase Eliminator. Total RNA was extracted using the 
RNeasy Plus Mini Kit (Qiagen, Cat# 74134) per manufacturers’ instructions for 
“Extraction from Animal cells” (Qiagen website: 
https://www.qiagen.com/us/resources/resourcedetail?id=14e7cf6e-521a-4cf7-8cbc-
bf9f6fa33e24&lang=en). Briefly, cell samples are first lysed and then homogenized as 
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indicated in the instructions, adding ethanol to provide ideal RNA binding conditions. 
Lysates are then loaded into the RNeasy Mini spin column where RNA binds to the silica 
membrane and all contaminants are washed away using the buffers provided in the kit. 
Pure, concentrated RNA is eluded in RNase-free water (provided).  
The first step requires RNAprotect Cell Reagent that can be purchased separately. 
For a T75 flask, 1 ml or RNAprotect was added, and for one well in a 6-well plate 500 µl 
were added. For homogenizing the lysate, “Step 5b” was done using a 1 mL syringe and a 
25-gauge needle. As with the miRNeasy kit, all optional steps were followed. For “Step 
14”, 30 µl of RNase-free water were used to elude the RNA into the collection tube 
twice. Before starting the procedure, 70% ethanol must be prepared and RLTPlus (2 mL) 
must be made using the RLT buffer provided and the beta mercaptoethanol (20 µL) 
stored in the 4°C fridge. Be sure to inspect the kit before use, and add the necessary 
components to each buffer. The lids of each bottle will specify what must be added and 
will allow for a check mark to be written if this step was done previously.  
After extraction, RNA was quantified using the NanoDrop spectrophotometer. Be 
sure to look for A260/280 ratios of around 2.0, indicating that the sample is pure RNA. A 
low A260/280 ratio (below 1.8) is indicative of contamination with phenol, TRIzol, or 
other aromatic compounds that are used in the extraction process and may appear in the 
sample if the washing steps were not complete. Thus, the A260/280 ratio should always 
be as close to 2.0 for RNA, and around 1.8 for “pure” DNA. 
 
Quantitative Real-Time PCR 
The iScript cDNA synthesis kit (BioRad, Cat# 1708891) was used to reverse 
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transcribe RNA (0.5µg) into cDNA following manufacturers’ instructions. Use the 
concentration determined by the NanoDrop to calculate the RNA concentration required. 
Briefly, buffer mix was prepared for all reactions, adding in the following order (per 
reaction): 4 µl iScript Reaction Mix, 0.5 µg RNA template, 1 µl iScript Reverse 
transcriptase, and nuclease-free water to attain a final volume of 20 µl. Reaction was 
mixed thoroughly by pipetting up and down and added to a 96-well qPCR plate. The 
plate was sealed with adhesive film and placed in the thermal cycler with the following 
conditions: 5 mins at 25°C, 20 mins at 46°C, 1 min at 95°C, and hold at 4°C. cDNA is 
very stable and can be stored in the -20 freezer. In addition, from this point on, ethanol is 
sufficient for cleaning the workspace.  
qPCR was done using the MyiQ real-time PCR detection system using iQ SYBR 
Green Supermix (BioRad, Cat# 1708882) following the manufacturer’s directions. 
Primer sequences are listed in Chapter 2, Table 4. Primers were commercially 
synthesized by Integrated DNA Technologies (IDT) and prepared adding 8 µl of the 
reverse and forward primers in 64 µl of nuclease-free water. For one reaction, 12.5 µl of 
SYBR green master mix, 1 µl of primer mix, and 10.5 µl of nuclease-free water were 
added together and placed on ice. Then, 1 µl of cDNA was added to the 96-well qPCR 
plate and 24 µl of the reaction mix was added to the corresponding well. Each primer had 
a different reaction mix. The cycling conditions were 95°C for 15 min, 95°C for 15s, 
60°C for 60s for 35 cycles, followed by melt analysis from 60 to 95°C. Expression levels 
were normalized to the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). Samples were analyzed in at least four independent biological replicates 
performed in triplicates. Depending on the cell lines used and treatments being compared, 
 147 
it may be necessary to optimize housekeeping genes since certain treatments may cause 
changes in transcript expression. For example, treating cells with dexamethasone or DTX 
may alter !-actin mRNA expression in some cell lines. Ensuring stable housekeeping 
gene expression between the control and test sample is crucial to getting reliable mRNA 
fold changes.  
 
Tumorsphere Forming Assays 
 PC3, PC3-DR, DU145, and DU145-DR cells were cultured in 6-well non-tissue 
culture treated plates at a density of 25,000 cells/ml, and suspended in F12K/RPMI 
medium supplemented with 1% knockout serum replacement (Fisher Scientific Cat# 
10828028), 20 ng/ml human EGF (Millipore Sigma Cat# E9644), 10 ng/ml human bFGF 
(PeproTech Cat# 100-18B), 0.1% of albumin solution (35% in PBS) (Sigma Cat# 
091M8416), 1% Pen-Strep, 0.1% insulin (Millipore Sigma Cat# 10516), and 0.1% 
selenium (Millipore Sigma Cat# 229865). 50 mL of F12K medium (500 mL bottle) and 
50 mL of RPMI medium (500 mL bottle) were removed inside the sterile hood and the 
EGF, FGF, and insulin were added outside the hood and filtered with a 10 mL syringe 
filter and added to the sterile media bottles. After 24 hours, the medium along with the 
floating cells were re-plated into a new 6-well non-tissue culture treated plate to remove 
any attached cells. Cells were left for 14 days and medium was added as needed. To 
visualize tumorsphere formation, images of cells were taken after 14 days post-plating 
using an Olympus 1X70 Microscope with phase contrast and Hofmann Modulation 
Contrast (HMC), equipped with a SPOT RT3 imaging system. Images were taken of 
multiple fields using 4X objective for quantification of % tumorsphere by area.  
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Flow Cytometric Analysis of Stem Cell Markers, ALDH activity, and Cell Death 
 Adherent PC3, PC3-DR, DU145, and DU145-DR cells were cultured in 
monolayer as previously described. Cells were washed with PBS and harvested using 
trypsin, followed by incubation in fresh fully supplemented complete RPMI medium for 
30 minutes to allow for N-Cadherin and E-Cadherin recycling following enzymatic 
cleavage. Tumorspheres derived from PC3-DR and DU145-DR cells were collected in a 
15 ml tube and dissociated using 500 µl-1000 µl of trypsin pipetting up and down 
vigorously for 2-5 minutes. Complete RPMI medium was added to the tube for recovery.  
 After a 30-minute recovery period, 1.0x 105 cells were plated in a 96 well plate 
skipping every other well on each side and labeled with antibodies against CD44 (BD 
Biosciences, Cat# 561292), CD24 (BD Biosciences, Cat# V13242), CD133 (Miltenyi, 
Cat# 130-098-142), CD117 (Miltenyi, Cat# 130-099-327), N-Cadherin (BD Biosciences, 
Cat# 555428), E-Cadherin (Miltenyi Biotec, Cat# 130-099-129) or annexin-V for 15 
minutes at room temperature. Cells were washed and resuspended in annexin binding 
buffer and analyzed immediate on the MACSQuant Analyzer 10 equipped with violet, 
blue, and red lasers (Miltenyi Biotec). Post-acquisition data analysis was performed using 
FlowJo version 10.08.1 (BD).  
 Data analysis started with gating for intact cells by comparing forward scatter 
(FSC-A) to side scatter (SSC-A) and then doublet discrimination using FSC-H/FSC-A 
profiles. Doublet discrimination is important because it ensures that only single cells are 
counted and not two cells clumped together with an artificially enhanced signal. Single-
stained samples were used to compensate negative matrices. Dead cells were then 
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compensated based on annexin-V positivity and only live cells were assessed for putative 
CSC marker expression.  
 ALDH+ activity was detected using an Aldefluor assay kit purchased from Stem 
Cell Technologies (Cat# 01700) following manufacturer’s instructions. 2D (monolayer) 
and 3D (tumorsphere) cells were prepared and harvested as described above in a 
microcentriguge tube. 4.0x105 cells were resuspended in 200 µl of aldefluor buffer 
(provided by the kit) and 2 µl of aldefluor reagent (provided) were added to form the 
“test” sample. 200 µl of the text mix were then immediately transferred to another 
microcentrifuge tube containing 2 µl of DEAB reagent (provided) to inactivate the 
aldefluor reagent and become the “control” sample. To get an accurate control reagent it 
is important to transfer the 200 µl to the DEAB reagent after less than 5-10 seconds 
because this stops the reaction and allows for an accurate baseline control. Both the 
control and test sample were incubated for 45 minutes at 37°C (in CO2 incubator). 
Samples were then centrifuged and resuspended in aldefluor buffer into round bottom 
glass cuvettes to be analyzed immediately on the MACSQuant Analyzer. Data analysis 
was done on FlowJo version 10.08 (BD) with gates drawn on the control DEAB+ 
samples for the negative gate and the positive gate was drawn on the sample predicted to 
have the most ALDH+ activity (PC3-DR, DU145-DR). This means that each cell line 
tested will have a different positive and negative gate. 
Running the MACSQuant requires training and guidance from the Flow 
Cytometry Core, managed by Dr. Kimberly Payne’s Laboratory. Before using the 
machine be sure to get help from a lab member that has extensive experience running it to 
ensure it is set up properly and cleaned before and after use. The antibodies used in this 
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experiment were previously titrated by running a pilot with various concentraions (low 
and high) of antibody to determine which dilution falls witin the voltage range. 
Therefore, it is not necessary to adjust the voltage of the antibody channels. It is 
necessary, however, to adjust the voltage for SSC/FSC to ensure that the cells are within 
the view screen. This is crucial for accurate analysis and is done using the Unstained 
sample. For ALDH analysis, it is necessary to adjust the voltage of the aldefluor gate 
using the control and test sample with the highest predicted ALDH+ activity to ensure 
that the cells appear within the view screen window.  
 
Detection of Cell Viability by Propidium Iodide staining 
 PC3, DU145, PC3-DR, and DU145-DR cells were seeded in 6-well plates at 
1.25x105 cells per well and allowed to adhere for 24 hours. Separately, PC3-DR and 
DU145-DR cells were seeded in non-adherent conditions in 6-well plates at 5 x104 cells 
per well and treated with 10 nM DTX for 72 hours, followed by PI staining using the 
Dead Cell Apoptosis Kit for flow cytometry (Life Technologies, Cat# V13242). Adherent 
cells were detached from culture flasks or dishes using trypsin for 30 seconds, followed 
by neutralization using complete RPMI medium containing 10% FBS. Cells grown in 
non-adherent conditions were collected from culture medium and dissociated also using 
trypsin. Cells were washed with PBS, suspended in annexin-V binding buffer and stained 
with propidium iodide (PI) (1µg/ mL final concentration) for 15 minutes at room 
temperature in the dark, then immediately analyzed on a MACSQuant Analyzer. Analysis 
included identification of intact cells (exclusion of debris), doublet discrimination, and 
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compensation using single stained cells for negative and positive gates. Data is then 
presented as cells staining negative for PI (percent viability).  
 
Cell Migration Assay  
 To evaluate migratory potential/response of PC3 and DU145 compared to their 
chemoresistant counterparts a scratch wound-healing assay was performed. Cells were 
seeded and grown to 100% confluency in 6-well plates in complete RPMI medium (with 
DTX added for the resistant cell lines). Three wound areas were generated per well by 
scratching three lines across the confluent monolayer cell surface with a 200 µl pipette 
tip. Be careful not to scratch too hard since this may damage the surface of the flask, 
preventing cells from migrating into the wound. Images of the wound areas were taken at 
0, 24, and 48 hours using the Olympus 1X70 inverted microscope equipped with SPOT 
RT3 Imaging System using a 4X phase contrast or HMC objective. To determine the 
exact spot where the 0-hour image was taken for the subsequent time points, a circle was 
drawn on the plate lid. Percent wound recovery was determined using Image J software 
measuring 6 randomly drawn lines across the wound at each time point used.  
 
MTT Viability Assay 
 PCa cells were seeded in 96-well plates at densities of 5x104 or 8x104 cells per 
well and allowed to grow for 24 hours. Cells were then treated with and without 10 nM 
DTX (in triplicates) in the presence or absence of LEDGF/p75 small molecule inhibitors 
(SMIs) for 48, 72 and 96 hours. In other experiments, single or double knockdowns of 
LEDGF/p75 or CLU were performed in PCa cells as described in Chapter 3. Cell 
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morphology was visualized in control and treated cells using the inverted Olympus IX70 
microscope equipped with HMC and imaging system.  
To assess cell viability, a modified 3-(4,5-dimethylthiazol- 2-yl)-2,5- 
diphenyltetrazolium bromide (MTT) colorimetric assay (Sigma-Aldrich) was performed. 
This assay indirectly measures the activity of NAD(P)H dehydrogenases, which reduce 
the yellow MTT substrate into its insoluble formazan, which has a purple/dark blue color 
in viable cells. The activity of these dehydrogenases often correlates with cell viability 
and decreases during cell death. It can be also slowed down in cells that are not rapidly 
proliferating or are metabolically compromised, which could be wrongly interpreted as 
cell death. The MTT substrate was prepared in dPBS (1 mg/1 mL) and 25 µl was added 
to each well and placed in the incubator. After a max 2-hour incubation, the plate was 
spun down (to collect and accurately count all floating cells, which are typically derived 
from mitotic or dead cells). This centrifugation step is critical when treating cells with 
DTX and other taxane drugs, which arrest cells in mitosis leading to their detachment 
from the bottom surface of the plates without causing immediate death. After 
centrifugation the MTT/medium supernatant was pipetted off the wells (do not aspirate), 
150 µl of DMSO were then added to each well, and the plate was placed on the shaker to 
dissolve the crystals into a colored solution. Absorbance of this solution was measured at 
460 and 490 nm using a spectrophotometer. Values were normalized to the absorbance 
obtained for the untreated control cells. Given that the MTT reagent is light sensitive 
most of the steps were conducted in the dark.  
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Statistical Analysis 
 GraphPad Prism 6 was used for statistical analysis for these studies. Differences 
between each group (expression, viability, etc.) were analyzed using unpaired Student’s t-
test. ANOVA was utilized when comparing multiple groups and P values below 0.05 
were considered statistically significant  (*P < 0.05; ** P < 0.01; ***P < 0.001).  
 
Final Remarks 
 Additional protocols for experiments not shown in this dissertation, and specific 
details pertaining to each experiment can be found in the Christina Cajigas-Du Ross’ 
laboratory notebooks and electronic files stored in the Casiano Laboratory at Loma Linda 
University Center for Health Disparities and Molecular Medicine (Mortensen Hall rooms 
102-103).  
